Combination of 15-PGDH inhibitors with corticosteroids and / or TNF inhibitors and uses thereof

Combining 15-PGDH inhibitors with corticosteroids and TNF inhibitors addresses the limitations of corticosteroid treatments by enhancing efficacy and reducing adverse effects in inflammatory and immune disorders.

JP7595413B2Active Publication Date: 2024-12-06CASE WESTERN RESERVE UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2019528506
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2017-05-23
Filing Date
2017-11-30
Publication Date
2024-12-06
Estimated Expiration
2037-11-30

AI Technical Summary

Technical Problem

Current treatments with corticosteroids for inflammatory and immune disorders are limited by adverse effects and reduced efficacy due to induction of 15-PGDH, which degrades prostaglandins crucial for healing and immune regulation.

Method used

Combining 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors to attenuate adverse effects and enhance therapeutic efficacy by maintaining prostaglandin levels.

Benefits of technology

Enhances anti-inflammatory and immunosuppressive effects of corticosteroids while reducing adverse effects, allowing higher doses and prolonged use, improving treatment of inflammatory and immune disorders.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595413000054
    Figure 0007595413000054
  • Figure 0007595413000055
    Figure 0007595413000055
  • Figure 0007595413000056
    Figure 0007595413000056
Patent Text Reader

Abstract

A method for treating an intestinal, gastrointestinal or bowel disorder in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor, alone or in combination with a corticosteroid and / or a TNFα antagonist. [Selected Figure] Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 62 / 428,259, filed November 30, 2016, and U.S. Provisional Application No. 62 / 510,166, filed May 23, 2017, both of which are incorporated by reference in their entireties herein.

[0002] Government funding This invention was made with Government support under Grant Nos. DK150964 and CA150964 awarded by the National Institutes of Health. The United States Government has certain rights in the invention. [Background technology]

[0003] background Short-chain dehydrogenases (SCDs) are a family of dehydrogenases that share only 15%-30% sequence identity, with similarities mainly in the coenzyme- and substrate-binding domains. In addition to their role in ethanol detoxification, SCDs are involved in the synthesis and degradation of fatty acids, steroids and several prostaglandins and are therefore implicated in a variety of disorders, including lipid storage diseases, myopathies, SCD deficiencies and certain genetic disorders.

[0004] The SCD 15-hydroxy-prostaglandin dehydrogenase (15-PGDH) (hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide); 15-PGDH; enzyme number 1.1.1.141; encoded by the HPGD gene) is a key enzyme in the inactivation of several active forms of prostaglandins, leukotrienes and hydroxyeicosatetraenoic acids (HETEs), e.g., by catalyzing the oxidation of PGE2 to 15-keto-prostaglandin E2 (15k-PGE). The human enzyme is encoded by the HPGD gene and consists of a homodimer with a subunit size of 29 kDa. The enzyme belongs to the evolutionarily conserved short-chain dehydrogenase / reductase enzyme (SDR) superfamily and has been named SDR36C1 according to the recently approved human enzyme nomenclature. So far, two forms of 15-PGDH enzyme activity have been identified: NAD+-dependent type I 15-PGDH (encoded by the HPGD gene) and type II NADP-dependent 15-PGDH (also known as carbonyl reductase 1 (CBR1, SDR21C1)). However, the NADP preference of CBR1 and the high Km value of CBR1 for most prostaglandins suggest that the majority of the in vivo activity can be attributed to type I 15-PGDH encoded by the HPGD gene (hereinafter and throughout the following text, simply referred to as 15-PGDH). Summary of the Invention

[0005] overview The embodiments described herein relate to the use of 15-PGDH inhibitors in combination with corticosteroids and TNF inhibitors to treat inflammation, reduce abnormal activity of the immune system, and / or promote wound healing in a subject in need thereof. It has been found that corticosteroids administered to a subject can induce the expression of 15-PGDH in the tissues of the subject. It has been found that administration of 15-PGDH inhibitors in combination with corticosteroids enhances the anti-inflammatory and / or immunosuppressive effects of corticosteroids while attenuating the adverse and / or cytotoxic effects induced by corticosteroids. Treatment of inflammatory disorders, immune disorders, and / or wounds by administration of 15-PGDH inhibitors in combination with corticosteroids can enhance the therapeutic effect of corticosteroids, and in some cases, may allow corticosteroids to be administered at lower doses to achieve similar effects, and in other cases, at higher doses and for longer periods of time while attenuating and / or reducing adverse or cytotoxic effects.

[0006] In some embodiments, the inflammatory and / or immune disease or disorder treated with the combination of 15-PGDH inhibitors and corticosteroids and TNF inhibitors may include intestinal, gastrointestinal or intestinal disorders.As described below, it has been found that an inhibitor of short-chain dehydrogenase activity (such as 15-PGDH inhibitors) can be administered to a subject in need thereof alone or in combination with a corticosteroid and / or a tumor necrosis factor (TNF)-α antagonist to treat intestinal, gastrointestinal or intestinal disorders (such as oral ulcers, gingival disease, gastritis, colitis, ulcerative colitis, gastric ulcers, inflammatory bowel disease and Crohn's disease).

[0007] In other embodiments, 15-PGDH inhibitors can be used as glucocorticoid sensitizers to treat glucocorticoid insensitivity in subjects who experience corticosteroid dependency or corticoid resistance or refractoriness or intolerance to corticosteroids, restore corticosteroid sensitivity, enhance glucocorticoid sensitivity, and / or reverse glucocorticoid insensitivity.For example, 15-PGDH inhibitors can be administered to subjects in combination with corticosteroids to treat glucocorticoid insensitivity in subjects who experience corticosteroid dependency or corticoid resistance or refractoriness or intolerance to corticosteroids, restore corticosteroid sensitivity, enhance glucocorticoid sensitivity, and / or reverse glucocorticoid insensitivity.

[0008] 15-PGDH inhibitors may also be administered to a subject in combination with corticosteroids and / or TNF inhibitors to promote wound healing, tissue repair and / or tissue regeneration and / or tissue graft survival or regeneration.

[0009] In some embodiments, the 15-PGDH inhibitor may be administered to a subject in an amount effective to increase prostaglandin levels and attenuate corticosteroid-induced adverse and / or cytotoxic effects in the subject. The 15-PGDH inhibitor includes a compound represented by formula (I): [ka] A compound having the formula: n is 0 to 2; Y 1 , Y 2 and R 1 are the same or different and are hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), and combinations thereof; Y 1 and Y 2 may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2is H, lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, X 1 and X 2 is independently N or C, where X 1 and / or X 2 If N, then Y 1 and / or Y 2 do not exist, Z 1 is O, S, CR a R b or NR a where R a and R b are independently H or C which is linear, branched or cyclic and unsubstituted or substituted. 1~8 is alkyl, Compounds and their pharma- ceutically acceptable salts may be included.

[0010] In other embodiments, the 15-PGDH inhibitor has the following formula (V): [ka] A compound having the formula: n is 0 to 2; X 6 are independently N or CR c and R 1 , R 6 , R 7 and R c are each independently hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O- )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 6 and R 7 may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2 is H, lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, Compounds and their pharma- ceutically acceptable salts may be included.

[0011] In some embodiments, R 1 is a branched or linear alkyl group containing -(CH2)n1CH3 (n1=0-7), [ka] wherein n2=0-6 and X is any of the following: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 ,CN,N(R 73 )2, [ka]

[0012] In other embodiments, R 6 and R 7 may each independently be one of the following: [ka] Each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72 , R 73 and R 74 are the same or different and independently represent hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 aryl, heterocycloalkenyl containing 5 to 6 ring atoms (wherein 1 to 3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), heteroaryl or heterocyclyl containing 5 to 14 ring atoms (wherein 1 to 6 of the ring atoms are independently selected from N, NH, N(C1-C3 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, silyl, hydroxyl, sulfhydryl, C1-C 24Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), sulfanamide (-SON(R); where R is independently H, alkyl, aryl, or heteroaryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5-C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether (-[(CH2) n O] m ), phosphate, phosphate ester [-OP(O)(OR)2; where R=H, methyl or other alkyl]; groups incorporating an amino acid or other moiety that is expected to carry a positive or negative charge at physiological pH; and combinations thereof, and pharma- ceutically acceptable salts thereof.

[0013] In some embodiments, the 15-PGDH inhibitor has an IC of less than 1 μM at a recombinant 15-PGDH concentration of about 5 nM to about 10 nM. 50 or preferably an IC of less than 250 nM 50 or more preferably an IC of less than 50 nM 50 or more preferably an IC of less than 10 nM 50or more preferably an IC of less than 5 nM 50 and can inhibit the enzymatic activity of recombinant 15-PGDH.

[0014] In other embodiments, the corticosteroid is aclovate, alclomethasone dipropionate, amcinafel, amcinafide, amcinonide, aristocort A, augmented betamethasone dipropionate, beclamethasone, beclopmethasone dipropionate, betamethasone, betamethasone benzoate, betamethasone-17-benzoate, betamethasone dipropionate, betamethasone acetate and betamethasone sodium phosphate andacetate), betamethasone valerate, betamethasone-17-valerate, chloroprednisone, clobetasol propionate, clobetasone propionate, clocortelone, cordran, corticosterone, cortisol, cortisol acetate, cortisol cypionate, cortisol sodium phosphate, cortisol sodium succinate, cortisone, cortisone acetate, cortodoxone, cyclocort, deflazacort, defluprednate, descinolone, desonide, desowen, desoxymethasone, desoxycorticosterone acetate, desoxycorticosterone pivalate, 11- Desoxycortisol, dexamethasone, dexamethasone acetate, dexamethasone sodium phosphate, dichlorisone, diflorasone diacetate, dihydroxycortisone, diprolen, diprolene, diprosone, esters of betamethasone, florone, flucetonide, flucloronide, flucortolone, fludrocortisone, fludrocortisone acetate, flumethalone, flumethasone, flumethasone pivalate, flunisolide, fluocinolone acetonide, fluocinolone acetonide acetate acetonide acetate, fluocinonide, fluorametholone, fluorocortisone, fluperolone, fluprednisolone, flurandrenolide, fluroandrenolone acetonideacetonide, fluticasone propionate, fuprednisolone, halcinonide, halobetasol propionate, halog, hydrocortamate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, hydrocortisone-17-valerate, kenalog, lidex, locold, locorten, maxif lor), medrysone, meprednisone, methylprednisolone, 6α-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisone, mometasone furoate, paramethasone, paramethasone acetate, prednidone, prednisone, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone tebutate tebutate, prednisone, psorcon, synalar, temovate, tetrahydrocortisol, topicort, topicort LP, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacotonide, tridesilone, valisone and westcoat. [Brief description of the drawings]

[0015] [Figure 1] FIG. 1 illustrates a graph showing the mean change from baseline body weight for a cohort of control (diamonds) and SW033291 (squares) treated mice, all treated with 2% dextran sulfate sodium (DSS) in drinking water. [Diagram 2] FIG. 2 illustrates a graph of the daily disease activity index for a cohort of control (diamonds) and SW033291 (squares) treated mice, all treated with 2% DSS in drinking water. [Diagram 3] FIG. 3 depicts a graph showing the mean change from baseline body weight for cohorts of DSS-treated mice given vehicle control (diamonds) or SW033291 (squares). [Figure 4] FIG. 4 (A-B) illustrates (A) a graph showing the number of ulcers in the colon of DSS-treated mice given control vehicle or SW033291; and (B) photographs showing ulcers in DSS-treated mice given control (left) or SW033291 (right). [Diagram 5] FIG. 5 depicts a graph showing quantification of ulcer burden at day 15 in DSS-treated mice given control vehicle or SW033291. [Figure 6] FIG. 6 (A-B) illustrates photographs showing colonoscopic findings and mouse endoscopic index of colitis severity (MEICS) for DSS-treated mice given control vehicle or SW033291. [Figure 7] FIG. 7 depicts a graph showing the MEICS scores of DSS-treated mice given control vehicle or SW033291. [Figure 8] FIG. 8 illustrates photomicrographs of high power fields of the central colon of control mice, SW033291-treated mice (Treatment) and 15-PGDH knockout mice (KO) on day 8 of the DSS protocol and a graph showing the average total number of BrdU positive cells per crypt in the distal and central colon of control (Cn), SW033291-treated mice (Tx) and 15-PGDH knockout mice (KO) on days 1, 8 and 15 of the DSS treatment protocol. [Figure 9] FIG. 9 depicts a graph showing colon length at day 22 in DSS-treated mice given control vehicle or SW033291. [Figure 10]FIG. 10 is a schematic diagram showing PARADIGM SuperPathway subnetworks whose activities are significantly correlated with the expression of the 15-PGDH gene in normal colon tissue. [Figure 11] FIG. 11 (A-C) illustrates (A) a schema of a study in which mice were dosed with dexamethasone daily for three days and sacrificed for analysis 6 hours after the third dose; (B) a representative Western blot analysis showing dexamethasone induction of 15-PGDH protein in mouse colon at two different doses of dexamethasone; and (C) a graphical summary of real-time RT-PCR from all mice in the study showing that dexamethasone treatment nearly doubled colonic 15-PGDH expression levels. [Figure 12] FIG. 12 (A-B) illustrates (A) a schema of a study in which mice were administered dexamethasone daily for three days and sacrificed for analysis 6 hours after the third dose; and (B) a graph showing that 15-PGDH enzymatic activity nearly doubled in the colon of dexamethasone-treated mice. [Figure 13] FIG. 13 (A-B) depicts graphs showing that higher dexamethasone doses exacerbate the induction of colitis by DSS. [Figure 14] FIG. 14 illustrates a schema of a study in which mice were given 2.5% DSS in drinking water for 7 days (days 1 to 8), a regime that induces colitis in the mice, and then treated with vehicle, (+)SW033291, dexamethasone, or both (+)SW033291 and dexamethasone. [Figure 15] FIG. 15 illustrates plots showing daily mouse body weights on days 1-17 of the study in mice treated with (+)SW033291 and dexamethasone, respectively or in combination. [Figure 16] FIG. 16 illustrates plots of disease activity (DAI) as measured by the combined disease activity index (scale of 0-6) of diarrhea (scale of 0-3) and blood in the feces (scale of 0-3) in mice treated with (+)SW033291 and dexamethasone, individually or in combination. [Figure 17] FIG. 17 (A-B) illustrates graphs of the results from FIG. 16 showing area under the DAI curve (total DAI) on the left and a graph of percent reduction in total DAI (relative disease reduction) on the right. [Figure 18] FIG. 18 illustrates a graph showing daily mouse survival for each treatment group through day 16 of the disease model. [Figure 19] FIG. 19 illustrates a graph of the data shown in FIG. 17B with the p-values ​​added and the groups permuted. [Figure 20] FIG. 20 (A-D) shows representative endoscopic images of each treatment group on day 13 of treatment. [Figure 21] Figure 21 illustrates a graph showing the Mouse Endoscopic Index of Colitis Severity (MEICS) scores on day 13 for each treatment group. **p<0.01, ***p<0.005 by ANOVA and Student's t-test. [Figure 22] Figures 22A-D show representative histology of the distal colon at day 13 for each treatment group: (A) control, (B) dexamethasone, (C) SW033291, and (D) combination. [Figure 23] FIG. 23 graphically depicts the histological extent of inflammatory damage to the crypts as scored semiquantitatively. [Figure 24] FIG. 24 graphs the severity of mesenteric lymphadenopathy, as assessed by collective mesenteric lymph node weight normalized to body weight, for each treatment group on day 13. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] Detailed Description For convenience, certain terms used in the specification, examples, and appended claims are collected here. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.

[0017] The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.

[0018] The terms "comprise," "comprising," "include," "including," "have," and "having" are used in an inclusive and open sense, meaning that additional elements may be included. The terms "such as," "eg," and "eg" as used herein are non-limiting and for descriptive purposes only. "Including" and "including but not limited to" are used interchangeably.

[0019] As used herein, the term "or" should be understood to mean "and / or" unless the context clearly dictates otherwise.

[0020] As used herein, the term "about" or "approximately" applies to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that differs by about 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% from a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the term "about" or "approximately" covers a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is within ±15%, ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2% or ±1% of the reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

[0021] It will be noted that some structures of the compounds of the present application contain asymmetric (chiral) carbon atoms or asymmetric (chiral) sulfur atoms. It should therefore be understood that isomers arising from such asymmetry are encompassed in the present application unless otherwise indicated. Such isomers can be obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. The compounds of the present application can exist in stereoisomeric forms and therefore may be produced as individual stereoisomers or as mixtures.

[0022] The term "isomerism" means compounds that have identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Stereoisomers that are not mirror images of one another are called "diastereoisomers," and stereoisomers that are non-superimposable mirror images are called "enantiomers," or sometimes optical isomers. A carbon atom bonded to four non-identical substituents is called a "chiral center," as is a sulfur bonded to three or four different substituents (e.g., a sulfoxide or sulfinimide).

[0023] The term "chiral isomer" refers to a compound having at least one chiral center. It has two enantiomeric forms of opposite chirality and can exist as individual enantiomers or as a mixture of enantiomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is called a "racemic mixture." A compound having two or more chiral centers has 2n-1 sets of enantiomeric pairs, where n is the number of chiral centers. A compound having two or more chiral centers can exist as individual diastereomers or as a mixture of diastereomers, called a "diastereomeric mixture." When one chiral center is present, a stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. Alternatively, when one or more chiral centers are present, a stereoisomer can be characterized as (+) or (-). Absolute configuration refers to the spatial arrangement of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked according to the Cahn-Ingold-Prelog precedence rules (Cahn et al, Angew.Chem.Inter.Edit. 1966, 5, 385;errata 511;Cahn et al., Angew.Chem. 1966, 78, 413;Cahn and Ingold, J Chem.Soc. 1951(London), 612;Cahn et al., Experientia 1956, 12, 81;Cahn,J., Chem.Educ. 1964, 41, 116).

[0024] The term "geometric isomer" refers to diastereomers whose existence results from hindrance of rotation about a double bond. These configurations are distinguished in their names by the prefixes cis and trans or Z and E, indicating that the groups are on the same or opposite sides of a double bond in the molecule according to the Cahn-Ingold-Prelog rules. Additionally, the structures and other compounds described in this application encompass all atropic isomers thereof.

[0025] The term "atropisomer" refers to a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropisomers owe their existence to restricted rotation caused by hindrance of rotation around the central bond of a large group. Such atropisomers typically exist as mixtures, although recent advances in chromatographic techniques have made it possible in certain cases to separate mixtures of two atropisomers.

[0026] The term "crystalline polymorphism" or "polymorphism" or "crystalline form" refers to crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystalline forms usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. Depending on the recrystallization solvent, crystallization rate, storage temperature and other factors, one crystalline form may predominate. Crystal polymorphs of a compound can be prepared by crystallization under different conditions.

[0027] The term "derivative" refers to compounds having a common core structure that are substituted with various groups, as described herein.

[0028] The term "bioisostere" refers to a compound resulting from the exchange of an atom or group of atoms with another roughly similar atom or group of atoms. The purpose of a bioisosteric exchange is to create a new compound that has biological properties similar to those of the parent compound. Bioisosteric exchanges can be based on physicochemical or topology. Examples of bioisosteres of carboxylic acids include sulfonimides, tetrazoles, sulfonates, and phosphonates. See, for example, Patani and LaVoie, Chem.Rev. 96, 3147-3176 (1996).

[0029] The expressions "parenteral administration" and "administered parenterally" are art-recognized terms and include modes of administration other than enteral and topical administration, such as injection, including, but not limited to, intravenous injection and infusion, intramuscular injection and infusion, intrapleural injection and infusion, intravascular injection and infusion, intrapericardial injection and infusion, intraarterial injection and infusion, intrathecal injection and infusion, intracapsular injection and infusion, intraorbital injection and infusion, intracardiac injection and infusion, intradermal injection and infusion, intraperitoneal injection and infusion, transtracheal injection and infusion, subcutaneous injection and infusion, subcuticular injection and infusion, intraarticular injection and infusion, subcapsular injection and infusion, subarachnoid injection and infusion, intraspinal injection and infusion, and intrasternal injection and infusion.

[0030] The term "treating" is art-recognized and includes inhibiting a disease, disorder, or condition in a subject (e.g., preventing its progression); and alleviating a disease, disorder, or condition (e.g., causing regression of a disease, disorder, and / or condition). Treating a disease or condition includes improving at least one symptom of a particular disease or condition, even if the underlying pathophysiology is unaffected.

[0031] The term "prevent" is art-recognized and includes stopping a disease, disorder, or condition from occurring in a subject who may be susceptible to, but has not yet been diagnosed as having, the disease, disorder, and / or condition. Preventing a condition associated with a disease includes stopping the condition from occurring after the disease has been diagnosed but before the condition has been diagnosed.

[0032] The term "pharmaceutical composition" refers to a formulation containing the disclosed compounds in a form suitable for administration to a subject. In a preferred embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a capsule, an IV bag, a tablet, a single pump of an aerosol inhaler, or a vial. The amount of active ingredient (e.g., a formulation of the disclosed compounds or salts thereof) in a unit dose of the composition is an effective amount and varies depending on the specific treatment involved. Those skilled in the art will understand that it may be necessary to routinely vary the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration. Various routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, intranasal, inhalation, and the like. Dosage forms for topical or transdermal administration of the compounds described herein include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, spray compounds, and inhalants. In a preferred embodiment, the active compound is mixed under sterile conditions with a pharma- ceutically acceptable carrier, and with any preservatives, buffers, or propellants that are required.

[0033] The term "flash dose" refers to a compound formulation that is in a rapidly dispersing dosage form.

[0034] The term "immediate release" is defined as the release of a compound from a dosage form in a relatively short period of time (generally up to about 60 minutes). The term "modified release" is defined to encompass delayed release, extended release, and pulsed release. The term "pulsed release" is defined as the successive release of drug from a dosage form. The term "sustained release" or "extended release" is defined as the continuous release of a compound from a dosage form over an extended period of time.

[0035] The expression "pharmaceutical acceptable" is art-recognized. In certain embodiments, the term includes compositions, polymers and other materials and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, within the scope of sound medical judgment, commensurate with a reasonable benefit / risk ratio.

[0036] The expression "pharmaceutical acceptable carrier" is art-recognized and includes, for example, a pharma- ceutically acceptable material, composition, or vehicle (such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material) involved in carrying or transporting any subject composition from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the subject composition and not harmful to the patient. In certain embodiments, pharma- ceutically acceptable carriers are non-pyrogenic. Some examples of materials which may serve as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil. (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffers; and (21) other non-toxic compatible substances used in pharmaceutical formulations.

[0037] The compounds of the present application can further form salts. All of these forms are also contemplated in the present application.

[0038] A "pharmaceutical acceptable salt" of a compound means a salt that is pharmaceutical acceptable and has the desired pharmacological activity of the parent compound. For example, the salt may be an acid addition salt. One embodiment of an acid addition salt is a hydrochloride salt. Pharmaceutically acceptable salts can be synthesized from parent compounds that contain a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid or free base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent, or in a mixture of the two (non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are generally preferred). A list of salts can be found in Remington's Pharmaceutical Sciences, 18th ed. (Mack Publishing Company, 1990).

[0039] The compounds described herein may also be prepared as esters (e.g., pharma- ceutically acceptable esters). For example, a carboxylic acid function in a compound may be converted to its corresponding ester (e.g., methyl ester, ethyl ester, or other ester). Also, an alcohol group in a compound may be converted to its corresponding ester (e.g., acetate, propionate, or other ester).

[0040] The compounds described herein may also be prepared as prodrugs (e.g., pharma- ceutically acceptable prodrugs). The terms "pro-drug" and "prodrug" are used interchangeably herein and refer to any compound that releases an active parent drug in vivo. Because prodrugs are known to improve many desirable qualities of pharmaceuticals (e.g., solubility, bioavailability, manufacturing, etc.), the compounds may be delivered in the form of prodrugs. Thus, the compounds described herein are intended to encompass prodrugs of the compounds claimed in this application, methods of delivering them, and compositions containing them. "Prodrugs" are intended to encompass any covalently bonded carriers that release the active parent drug in vivo when such prodrugs are administered to a subject. Prodrugs are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either by routine manipulation or in vivo, to the parent compound. Prodrugs include compounds in which a hydroxy, amino, sulfhydryl, carboxy, or carbonyl group is bonded to any group that can be cleaved in vivo to form a free hydroxyl, amino, sulfhydryl, carboxy, or carbonyl group, respectively. Prodrugs can also include precursors (precursors) of the compounds described herein that become active or more active pharmacological agents or active compounds described herein after undergoing chemical conversion by metabolic processes.

[0041] Examples of prodrugs include, but are not limited to, esters (e.g., acetate, dialkylaminoacetate, formate, phosphate, sulfate, and benzoate derivatives) and carbamates (e.g., N,N-dimethylaminocarbonyl) of hydroxy functional groups; ester groups (e.g., ethyl ester, morpholinoethanol ester) of carboxyl functional groups; N-acyl derivatives (e.g., N-acetyl), N-Mannich bases, Schiff bases, and enaminones of amino functional groups; oxime, acetal, ketal, and enol esters of ketone and aldehyde functional groups; and the like; and sulfides that are oxidized to form sulfoxides or sulfones.

[0042] The term "protecting group" refers to a group of atoms that, when attached to a reactive group in a molecule, masks, reduces or prevents that reactivity. Examples of protecting groups can be found in Green and Wuts, Protective Groups in Organic Chemistry, (Wiley, 2.sup.nd ed. 1991); Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols.1-8 (John Wiley and Sons, 1971-1996); and Kocienski, Protecting Groups, (Verlag, 3rd ed. 2003).

[0043] The term "amine protecting group" is intended to mean a functional group that converts an amine, amide, or other nitrogen-containing moiety into a different chemical group that is substantially inert to the conditions of a particular chemical reaction. Amine protecting groups are preferably easily and selectively removed in good yields under conditions that do not affect other functional groups of the molecule. Examples of amine protecting groups include, but are not limited to, formyl, acetyl, benzyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, t-butyloxycarbonyl (Boc), p-methoxybenzyl, methoxymethyl, tosyl, trifluoroacetyl, trimethylsilyl (TMS), fluorenyl-methyloxycarbonyl, 2-trimethylsilyl-ethyoxycarbonyl, 1-methyl-1-(4-biphenylyl)ethoxycarbonyl, allyloxycarbonyl, benzyloxycarbonyl (CBZ), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like. Those skilled in the art can identify other suitable amine protecting groups.

[0044] Representative hydroxy protecting groups include those where the hydroxy group is acylated or alkylated, such as benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.

[0045] Additionally, the salts of the compounds described herein may exist in either hydrated or non-hydrated (anhydrous) form, or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.

[0046] The term "solvate" refers to a solvent addition form that contains a stoichiometric or non-stoichiometric amount of solvent. Some compounds tend to trap a fixed molar ratio of solvent molecules in the crystalline solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate, and if the solvent is alcohol, the solvate formed is an alcoholate. Hydrates are formed by the combination of one or more water molecules with one of the substances in which water retains its molecular state as H2O, and such combinations can form one or more hydrates.

[0047] The compounds, salts and prodrugs described herein may exist in several tautomeric forms, including enol and imine forms and keto and enamine forms, as well as geometric isomers and mixtures thereof. Tautomers exist as a mixture of a set of tautomers in solution. In solid form, one tautomer usually predominates. Even if one tautomer may be described, the present application encompasses all tautomers of the compounds of the present invention. A tautomer is one of two or more structural isomers that exist in equilibrium and are easily converted from one isomer to another. This reaction results in the formal transfer of a hydrogen atom with the switch of adjacent conjugated double bonds. In solutions where tautomerization is possible, a chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are capable of interconversion by tautomerization is called tautomerism.

[0048] Of the various types of tautomerism possible, two are commonly observed: keto-enol tautomerism, in which a simultaneous shift of electrons and hydrogen atoms occurs.

[0049] Tautomerization can be catalyzed by: Bases: 1. Deprotonation; 2. Formation of delocalized anions (e.g. enolates); 3. Protonation at different positions of the anion; Acids: 1. Protonation; 2. Formation of a delocalized cation; 3. Deprotonation at a different position adjacent to the cation.

[0050] The term "analog" refers to a compound that is structurally similar to another but differs slightly in composition (such as the replacement of one atom with an atom of a different element or the presence of a particular functional group or the replacement of one functional group with another functional group). Thus, an analog is a compound that is similar or identical in function and appearance to the reference compound, but not similar or identical in structure or origin.

[0051] A "patient", "subject" or "host" treated by the subject method may refer to a human or non-human animal, such as a mammal, fish, bird, reptile or amphibian. Thus, the subject of the methods disclosed herein may be a human, a non-human primate, a horse, a pig, a rabbit, a dog, a sheep, a goat, a cow, a cat, a guinea pig or a rodent. The term does not denote a particular age or sex. Thus, it is intended to include adults and newborns, as well as fetuses, regardless of whether they are male or female. In one aspect, the subject is a mammal. A patient refers to a subject suffering from a disease or disorder.

[0052] The terms "prophylactic" or "therapeutic" treatment are art-recognized and include administration of one or more of the subject compositions to a host. If it is administered before the clinical appearance of an undesirable condition (e.g., a disease or other undesirable condition of a host animal), the treatment is prophylactic, i.e., it protects the host from the onset of the undesirable condition. On the other hand, if it is administered after the appearance of an undesirable condition, the treatment is therapeutic (i.e., it is intended to alleviate, ameliorate, or stabilize an existing undesirable condition or its side effects).

[0053] The terms "therapeutic agent", "drug", "medicine" and "bioactive agent" are art-recognized and include molecules and other agents that are biologically, physiologically or pharmacologically active substances that act locally or systemically in a patient or subject to treat a disease or condition. These terms include, but are not limited to, pharma- ceutically acceptable salts and prodrugs thereof. Such agents may be acidic, basic or salts; they may be neutral molecules, polar molecules, or molecular complexes capable of hydrogen bonding; they may be prodrugs in the form of ethers, esters, amides, etc., that become biologically activated when administered to a patient or subject.

[0054] The phrase "therapeutically effective amount" or "pharmaceutical effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a therapeutic agent that produces some desired effect at a reasonable benefit / risk ratio applicable to any medical treatment. In certain embodiments, the term refers to an amount necessary or sufficient to eliminate, reduce or maintain the target of a particular therapeutic regimen. An effective amount may vary depending on factors such as the disease or condition being treated, the particular targeting construct being administered, the size of the subject or the severity of the disease or condition. Those skilled in the art may empirically determine the effective amount of a particular compound without necessitating undue experimentation. In certain embodiments, a therapeutically effective amount of a therapeutic agent for in vivo use will likely depend on several factors, including the rate of release of the agent from the polymer matrix (which will depend in part on the chemical and physical properties of the polymer); the identity of the agent; the mode and method of administration; and any other materials incorporated into the polymer matrix in addition to the agent.

[0055] The term "ED50" is art-recognized. In certain embodiments, ED50 refers to the dose of a drug that produces 50% of its maximum response or effect, or the dose that produces a pre-determined response in 50% of test subjects or preparations. The term "LD50" is art-recognized. In certain embodiments, LD50 refers to the amount of a drug that is lethal in 50% of test subjects. The term "therapeutic index" is art-recognized and refers to the therapeutic index of a drug, which is defined as LD50 / ED50.

[0056] The term “IC 50 " or "half maximal inhibitory concentration" is intended to refer to the concentration of a substance (e.g., a compound or drug) required for 50% inhibition of a biological process, or a component of a process (including a protein, subunit, organelle, ribonucleoprotein, etc.).

[0057] For any compound, the present application is intended to include all isotopes of atoms occurring in the compounds of the present invention.Isotopes include atoms having the same atomic number but different mass numbers.By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include C-13 and C-14.

[0058] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom in the ring. When substituents are listed without indicating the atom through which such substituent is bonded to the remainder of the compound of a given formula, then such substituent may be bonded through any atom in such substituent. Combinations of substituents and / or variables are permissible, but only if such combinations result in stable compounds.

[0059] When an atom or chemical moiety is followed by a range of subscript numbers (e.g., C 1~6), which is intended to encompass each number within that range as well as all intermediate ranges. For example, "C 1~6 "Alkyl" is intended to include alkyl groups having 1, 2, 3, 4, 5, 6, 1-6, 1-5, 1-4, 1-3, 1-2, 2-6, 2-5, 2-4, 2-3, 3-6, 3-5, 3-4, 4-6, 4-5 and 5-6 carbons.

[0060] The term "alkyl" is intended to include both branched (e.g., isopropyl, tert-butyl, isobutyl) and straight chain (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl) groups, as well as cycloalkyl (e.g., alicyclic) groups (e.g., cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl), alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. Such aliphatic hydrocarbon groups have the number of carbon atoms specified. For example, C 1~6 Alkyl is intended to include C1 alkyl groups, C2 alkyl groups, C3 alkyl groups, C4 alkyl groups, C5 alkyl groups, and C6 alkyl groups. As used herein, "lower alkyl" refers to an alkyl group having 1 to 6 carbon atoms in the carbon chain backbone. "Alkyl" further includes alkyl groups having oxygen, nitrogen, sulfur or phosphorus atoms replacing one or more hydrocarbon backbone carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has 6 or fewer (e.g., 4 or fewer) carbon atoms in its backbone (e.g., C for straight chain). 1~ C6, C for branched chain 3~ Likewise, certain cycloalkyls have from 3-8 carbon atoms in their ring structure (for example, 5 or 6 carbons in the ring structure).

[0061] The term "substituted alkyl" refers to an alkyl moiety having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety. Cycloalkyl may be further substituted, e.g., with the substituents described above. An "alkylaryl" or "aralkyl" moiety is an alkyl substituted with an aryl (e.g., phenylmethyl (benzyl)). Unless otherwise indicated, the terms "alkyl" and "lower alkyl" include linear, branched, cyclic, unsubstituted, substituted, and / or heteroatom-containing alkyl or lower alkyl, respectively.

[0062] The term "alkenyl" refers to a straight chain, branched or cyclic hydrocarbon group of 2 to about 24 carbon atoms containing at least one double bond, such as ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl, cyclopentenyl, cyclohexenyl, cyclooctenyl, and the like. Generally, although again not necessarily, an alkenyl group may contain from 2 to about 18 carbon atoms, and more specifically, from 2 to 12 carbon atoms. The term "lower alkenyl" refers to an alkenyl group of 2 to 6 carbon atoms, and the specific term "cycloalkenyl" contemplates cyclic alkenyl groups, preferably having from 5 to 8 carbon atoms. The term "substituted alkenyl" refers to an alkenyl substituted with one or more substituents, and the terms "heteroatom-containing alkenyl" and "heteroalkenyl" refer to an alkenyl or heterocycloalkenyl (e.g., heterocyclohexenyl) in which at least one carbon atom has been replaced with a heteroatom. Unless otherwise indicated, the terms "alkenyl" and "lower alkenyl" include linear, branched, cyclic, unsubstituted, substituted, and / or heteroatom-containing alkenyl and lower alkenyl, respectively.

[0063] The term "alkynyl" refers to a straight or branched chain hydrocarbon group of 2 to 24 carbon atoms containing at least one triple bond, such as ethynyl, n-propynyl, and the like. Generally, but not necessarily, an alkynyl group may contain from 2 to about 18 carbon atoms, more specifically from 2 to 12 carbon atoms. The term "lower alkynyl" contemplates an alkynyl group of 2 to 6 carbon atoms. The term "substituted alkynyl" refers to an alkynyl substituted with one or more substituents, and the terms "heteroatom-containing alkynyl" and "heteroalkynyl" refer to an alkynyl in which at least one carbon atom is replaced with a heteroatom. Unless otherwise indicated, the terms "alkynyl" and "lower alkynyl" include straight chain, branched, unsubstituted, substituted, and / or heteroatom-containing alkynyl and lower alkynyl, respectively.

[0064] The terms "alkyl," "alkenyl," and "alkynyl" are intended to include moieties that are diradicals (i.e., have two points of attachment). A non-limiting example of such an alkyl moiety that is a diradical is -CHCH- (i.e., a C alkyl group covalently bonded to the remainder of the molecule through each terminal carbon atom).

[0065] The term "alkoxy" refers to an alkyl group attached through a single, terminal ether bond. That is, an "alkoxy" group may be represented as -O-alkyl, where alkyl is as defined above. A "lower alkoxy" group is intended to mean an alkoxy group containing 1 to 6 carbon atoms, and includes, for example, methoxy, ethoxy, n-propoxy, isopropoxy, t-butyloxy, and the like. Preferred substituents identified herein as "C1-C6 alkoxy" or "lower alkoxy" contain 1 to 3 carbon atoms, and particularly preferred such substituents contain 1 or 2 carbon atoms (i.e., methoxy and ethoxy).

[0066] The term "aryl" refers to an aromatic substituent containing a single aromatic ring or multiple aromatic rings that are fused, directly linked, or indirectly linked (such as different aromatic rings are bonded to a common group, such as a methylene or ethylene moiety). The aryl group may contain 5 to 20 carbon atoms, with particularly preferred aryl groups containing 5 to 14 carbon atoms. Examples of aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isoxazole, pyridine, pyrazine, pyridazine, pyrimidine, and the like. Additionally, the term "aryl" includes polycyclic aryl groups (e.g., tricyclic, bicyclic; e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine). Aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles," "heterocycles," "heteroaryls" or "heteroaromatics."The aromatic ring may contain at one or more ring positions a substituent as described above (e.g., halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonato, phosphinato, cyano, aryloxy ... The aryl groups may be substituted with aryl, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or aromatic or heteroaromatic moieties. Aryl groups may also be fused or bridged with alicyclic or heterocyclic rings that are not aromatic so as to form polycyclic ring systems (e.g., tetralin, methylenedioxyphenyl). Unless otherwise indicated, the term "aryl" encompasses aromatic substituents that are unsubstituted, substituted, and / or contain heteroatoms.

[0067] The term "alkaryl" refers to an aryl group having an alkyl substituent, and the term "aralkyl" refers to an alkyl group having an aryl substituent, where "aryl" and "alkyl" are defined above. Exemplary aralkyl groups contain 6 to 24 carbon atoms, with particularly preferred aralkyl groups containing 6 to 16 carbon atoms. Examples of aralkyl groups include, but are not limited to, benzyl, 2-phenyl-ethyl, 3-phenyl-propyl, 4-phenyl-butyl, 5-phenyl-pentyl, 4-phenylcyclohexyl, 4-benzylcyclohexyl, 4-phenylcyclohexylmethyl, 4-benzylcyclohexylmethyl, and the like. Alkaryl groups include, for example, p-methylphenyl, 2,4-dimethylphenyl, p-cyclohexylphenyl, 2,7-dimethylnaphthyl, 7-cyclooctylnaphthyl, 3-ethyl-cyclopenta-1,4-diene, and the like.

[0068] The term "heterocyclyl" or "heterocyclic group" includes closed ring structures (e.g., 3- to 10-membered or 4- to 7-membered rings) that include one or more heteroatoms. A "heteroatom" includes an atom of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, sulfur, and phosphorus.

[0069] Heterocyclyl groups may be saturated or unsaturated and include pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams (such as azetidinones and pyrrolidinones), sultams and sultones. Heterocyclic groups such as pyrrole and furan may have aromatic character. Heterocyclic groups such as quinoline and isoquinoline contain fused ring structures. Other examples of heterocyclic groups include pyridine and purine. The heterocycle may be optionally substituted at one or more positions with a substituent as described above (e.g., halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl, and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfate, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, or an aromatic or heteroaromatic moiety). The heterocyclic group may also be substituted at one or more of the constituent atoms by, for example, lower alkyl, lower alkenyl, lower alkoxy, lower alkylthio, lower alkylamino, lower alkylcarboxyl, nitro, hydroxyl, -CF3, or -CN.

[0070] The term "halo" or "halogen" refers to fluoro, chloro, bromo, and iodo. "Counterion" is used to represent small negatively charged species such as fluoride, chloride, bromide, iodide, hydroxide, acetate, and sulfate. The term sulfoxide refers to sulfur bonded to two different carbon atoms and an oxygen, where the SO bond can be illustrated as a double bond (S=O), an uncharged single bond (SO), or a charged single bond [S(+)-O(-)].

[0071] The term "substituted," as in "substituted alkyl," "substituted aryl," and the like, is intended to mean that at least one hydrogen atom bonded to a carbon (or other) atom in an alkyl, aryl, or other moiety, as mentioned in some of the definitions above, is replaced with one or more substituents other than hydrogen. Examples of such substituents include, but are not limited to, halo, hydroxyl, silyl, sulfhydryl, C1-C6 alkyl, C1-C6 aryl ... 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO-), carbamoyl (-(CO)-NH2), mono-(C1-C 24 Alkyl)-substituted carbamoyl (-(CO)-NH(C1-C 24 di-(C1-C4 alkyl)-substituted carbamoyl (-(CO)-N(C1-C 24 alkyl)2), monosubstituted arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + C - ), isothiocyanato (-S-CN), azido (-N=N + =N- ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), mono-(C1-C 24 Alkyl)-substituted amino and di-(C1-C 24 Alkyl)-substituted amino, mono-(C5-C 20 Aryl)-substituted amino and di-(C5-C 20 Aryl)-substituted amino, C2-C 24 Alkylamide (-NH-(CO)-alkyl), C6~C 20 Arylamide (-NH-(CO)-aryl), imino (-CR=NH; where R=hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), and phosphino (-PH2); and hydrocarbyl moieties C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C5-C 20 Aryl, C6-C 24Alkaryl and C6-C 24 Examples include aralkyl.

[0072] Additionally, the aforementioned functional groups may be further substituted, if a particular group permits, with one or more additional substituents or with one or more hydrocarbyl moieties (such as those specifically listed above).Similarly, the aforementioned hydrocarbyl moieties may be further substituted with one or more functional groups or additional hydrocarbyl moieties (such as those specifically listed above).

[0073] When the term "substituted" precedes a list of groups that may be substituted, it is intended that the term apply to all members of that group. For example, the phrase "substituted alkyl, alkenyl, and aryl" should be interpreted as "substituted alkyl, substituted alkenyl, and substituted aryl." Similarly, when the term "containing heteroatoms" precedes a list of groups that may contain heteroatoms, it is intended that the term apply to all members of that group. For example, the phrase "heteroatom-containing alkyl, alkenyl, and aryl" should be interpreted as "heteroatom-containing alkyl, substituted alkenyl, and substituted aryl."

[0074] "Optional" or "optionally" means that the subsequently described circumstance may or may not occur, and thus the description encompasses both cases where the circumstance occurs and cases where the circumstance does not occur. For example, the phrase "optionally substituted" means that non-hydrogen substituents may or may not be present on a given atom, and thus the description encompasses structures where non-hydrogen substituents are present and structures where non-hydrogen substituents are not present.

[0075] The terms "stable compound" and "stable structure" are intended to indicate a compound that is sufficiently robust to survive isolation, and, if necessary, purification from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0076] The term "free compound" is used herein to describe a compound in an unbound state.

[0077] Throughout the description, when a composition is described as having, including, or comprising certain components, it is contemplated that the composition may also consist essentially of or consist of the recited components. Similarly, when a method or process is described as having, including, or comprising certain process steps, the process may also consist essentially of or consist of the recited process steps. Furthermore, it should be understood that the order of steps or the order for performing certain actions is not important so long as the compositions and methods described herein remain operable. Moreover, two or more steps or actions may be performed simultaneously.

[0078] The term "small molecule" is an art-recognized term. In certain embodiments, the term refers to a molecule having a molecular weight of less than about 2000 amu, or less than about 1000 amu, or even less than about 500 amu.

[0079] All percentages and ratios used herein are by weight unless otherwise indicated.

[0080] The term "gene expression" or "protein expression" encompasses any information regarding the amount of gene transcript or protein present in a sample as well as information about the rate at which a gene or protein is produced, accumulated or degraded (e.g. reporter gene data, data from nuclear runoff experiments, pulse chase data, etc.). Certain types of data may be considered related to both gene and protein expression. For example, protein levels in a cell reflect the level of the protein as well as the level of transcription, and such data are intended to be encompassed by the expression "gene or protein expression information". Such information may be given in the form of amount per cell, amount relative to a control gene or protein, in a unitless measure, etc. The term "information" should not be limited to any particular means of presentation, but is intended to mean any presentation that provides the relevant information. The term "expression level" refers to the amount reflected in or that can be derived from gene or protein expression data, regardless of whether the data is directed to gene transcript accumulation or protein accumulation or protein synthesis rate, etc.

[0081] The terms "healthy" and "normal" are used interchangeably herein to refer to a subject or particular cell or tissue that is devoid of a disease state (at least to the limits of detection).

[0082] The term "nucleic acid" refers to polynucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to encompass analogs of either RNA or DNA made from nucleotide analogs, as well as single-stranded (such as sense or antisense) and double-stranded polynucleotides, where applicable to the described embodiment. In some embodiments, "nucleic acid" refers to inhibitory nucleic acid. Some categories of inhibitory nucleic acid compounds include antisense nucleic acids, RNAi constructs, and catalytic nucleic acid constructs. Such nucleic acid categories are well known in the art.

[0083] The term "corticosteroid resistance to the anti-inflammatory effects of corticosteroids" refers to the lack of clinical improvement after treatment with high doses of glucocorticoids.

[0084] The term "corticosteroid dependence" refers to a condition that initially responds to corticosteroids but rapidly relapses upon withdrawal or tapering of the dose.

[0085] The term "corticosteroid-refractory response" refers to failure to respond to adequate induction doses of corticosteroids. It encompasses responses that are relatively or completely refractory to glucocorticoid therapy and often need to be regulated by additional treatment.

[0086] Other types of corticosteroid ineffectiveness include the need for very high doses of treatment, "difficult to treat" and "inadequate response" or severe cases, and reduced responsiveness in vitro and in vivo.

[0087] The term "corticosteroid intolerance" refers to the toxicity of treatment and / or the risk of developing adverse events associated with corticosteroids, such as opportunistic infections and bone loss.

[0088] The embodiments described herein relate to the use of 15-PGDH inhibitors in combination with corticosteroids to treat inflammation and / or reduce abnormal activity of the immune system in a subject in need thereof. It has been found that corticosteroids administered to a subject can induce the expression of 15-PGDH in the tissues of the subject. It has been found that administration of 15-PGDH inhibitors in combination with corticosteroids enhances the anti-inflammatory and / or immunosuppressive effects of corticosteroids while attenuating the adverse and / or cytotoxic effects induced by corticosteroids. Treatment of inflammatory and / or immune disorders by administration of 15-PGDH inhibitors in combination with corticosteroids can enhance therapeutic effects, allowing corticosteroids to be administered in lower doses in some cases to achieve similar effects, and in other cases, at higher doses and for longer periods of time while attenuating and / or reducing adverse or cytotoxic effects. Further embodiments herein relate to the use of a 15-PGDH inhibitor in combination with a TNFα inhibitor to treat inflammation and / or reduce abnormal activity of the immune system in a subject in need thereof.

[0089] In some embodiments, 15-PGDH inhibitor can be administered in combination with corticosteroid and / or TNF inhibitor to treat intestinal, digestive or intestinal disorders. Treated intestinal, digestive or intestinal disorders can include oral ulcer, gingival disease, gastritis, colitis, ulcerative colitis, gastric ulcer, inflammatory bowel disease and Crohn's disease.As described below, it has been found that short-chain dehydrogenase activity inhibitor (such as 15-PGDH inhibitor) can be administered alone or in combination with corticosteroid to a subject in need thereof to treat intestinal, digestive or intestinal disorders (such as oral ulcer, gingival disease, gastritis, colitis, ulcerative colitis, gastric ulcer, inflammatory bowel disease and Crohn's disease).

[0090] The 15-PGDH inhibitors described herein may be used in pharmaceutical compositions for the prevention or treatment of oral, intestinal and / or gastrointestinal damage or disease or inflammatory bowel disease (IBD), such as Crohn's disease, oral ulcers, gum disease, gastritis, colitis, ulcerative colitis and gastric ulcers. Gastritis and gastric ulcers, representative gastrointestinal diseases, are defined as conditions in which the mucosa of the gastrointestinal tract is digested by gastric acid to form ulcers. In the stomach wall, which generally consists of the mucosa, submucosa, muscularis and serosa, gastric ulcers damage even the submucosa and muscularis, while gastritis only damages the mucosa. The incidence of gastritis and gastric ulcers is relatively high, but their causes remain unclear. So far, they are known to be caused by an imbalance between attacking and defensive factors, i.e., an increase in attacking factors (such as increased secretion of gastric acid or pepsin) or a decrease in defensive factors (structural or morphological defects in the gastric mucosa, decreased secretion of mucus and bicarbonate ions, decreased production of prostaglandins, etc.).

[0091] Currently available therapeutic agents for gastritis and gastric ulcers include various drugs for strengthening defense factors (such as antacids that do not affect gastric acid secretion but neutralize already produced gastric acid, inhibitors of gastric acid secretion, promoters of prostaglandin secretion, and coating agents for the stomach wall). In particular, prostaglandins are known to be essential for maintaining the mechanism for protecting and defending the gastric mucosa (Wallace J L., 2008, Physiol Rev., 88(4), 1547-65; SJ Konturek et al., 2005, Journal of Physiology and Pharmacology, 56(5)). In view of the above, the 15-PGDH inhibitors described herein exhibit suppressive or inhibitory activity against 15-PGDH, which degrades prostaglandins that protect the gastric mucosa, and therefore may be effective in preventing or treating gastrointestinal diseases (especially gastritis and gastric ulcers).

[0092] In addition, both corticosteroids and TNFα antagonists are used in the treatment of patients with ulcerative colitis and IBD. In mouse models, 15-PGDH inhibitors promote the healing of ulcerative colitis. We found that administration of corticosteroids to mice increases the level of 15-PGDH in the colon, an effect that should reduce the therapeutic efficacy of corticosteroids in the treatment of colitis. This suggests that combining corticosteroids with 15-PGDH inhibitors should be more effective in the treatment of colitis (and IBD) than using either agent alone.

[0093] Similarly, we have shown that TNFα suppresses colonic 15-PGDH expression, suggesting that TNFα antagonists will increase colonic 15-PGDH expression, an effect that should reduce the therapeutic efficacy of corticosteroids in treating colitis. This suggests that combining a TNFα antagonist (e.g., the chimeric antibody REMICADE (infliximab)) with a 15-PGDH inhibitor should be more effective in treating colitis (and IBD) than either agent alone.

[0094] In other embodiments, the 15-PGDH inhibitor and a corticosteroid or the 15-PGDH inhibitor and a TNF inhibitor may be provided in a topical composition or formulation used to treat inflammation and / or abnormal immune system activity associated with conditions such as atopic dermatitis, psoriasis, eczematous dermatitis, nummular dermatitis, irritant contact dermatitis, allergic contact dermatitis (such as exposure to poison ivy, exposure to poison sumac, and exposure to poison sumac), seborrheic dermatitis, stasis dermatitis, and other steroid-responsive skin diseases.

[0095] In other embodiments, the 15-PGDH inhibitor and a corticosteroid or the 15-PGDH inhibitor and a TNF inhibitor provided in a topical composition may be used to treat, for example, acne vulgaris, alopecia, alopecia greata, vitiligo, eczema, xerosis eczema, keratosis pilaris, lichen planus, lichen sclerosus, lichen linearis, lichen simplex chronicus, prurigo nodularis, discoid lupus erythematosus, lymphocytic infiltrate of Jessner / Kanof, lymphacytoma cutis, pyoderma gangrenosum, pruritis ani, sarcoidosis, chondrodermatitis nodularis helices, and other inflammatory skin diseases.

[0096] Conditions that may be treated with a 15-PGDH inhibitor and a corticosteroid or a 15-PGDH inhibitor and a TNF inhibitor may include, for example, keloids, hypertrophic scars, pretibial myxedema, and other infiltrative skin diseases. Additional conditions include, for example, granuloma annulare, diabetic necrobiosis lipoidica, sarcoidosis, and other non-infectious granulomas.

[0097] In yet another embodiment, the 15-PGDH inhibitor described herein can be administered in combination with corticosteroids or TNF inhibitors for wound healing, tissue regeneration and / or tissue repair.Among various prostaglandins, PGE2 is known to act as a mediator for wound healing.Therefore, subjects who are administered steroids (including those who are undergoing surgery to heal wounds) can be administered 15-PGDH inhibitors to enhance PGE2 and promote wound healing.

[0098] Furthermore, it has been shown that increasing the level of prostaglandins stimulates signaling through the Wnt signaling pathway via increasing the transcriptional activity mediated by β-catenin. Wnt signaling is known to be an important pathway utilized by tissue stem cells. Thus, the 15-PGDH inhibitors described herein may be utilized to increase the number of tissue stem cells, for purposes that may include promoting tissue regeneration or repair in subjects undergoing corticosteroid treatment. Furthermore, the 15-PGDH inhibitors described herein may be utilized to promote tissue regeneration or repair in additional organs, including but not limited to the brain, eye, cornea, retina, lung, heart, stomach, small intestine, pancreas, pancreatic β-cells, kidney, bone, cartilage, and peripheral nerves.

[0099] In other embodiments, 15-PGDH inhibitors may be used as glucocorticoid sensitizers to treat glucocorticoid insensitivity, restore corticosteroid sensitivity, enhance glucocorticoid sensitivity, and / or reverse glucocorticoid insensitivity in subjects experiencing corticosteroid dependence or corticoid resistance or refractoriness or intolerance to corticosteroids. The therapeutic effects of 15-PGDH inhibitors when used as glucocorticoid sensitizers include, but are not limited to, steroid sparing in corticosteroid-dependent patients, better response or tolerance to corticosteroids, achieving efficacy through the use of lower doses of corticosteroids, preventing individuals at risk of developing a refractory response or resistance or deterioration in response to exposure to antigens, infections, exercise or stimulants, achieving optimal immune function, milder response of a subject or patient when steroid administration is tapered or discontinued or after chronic administration of corticosteroids, reduced risk of developing adverse events associated with corticosteroids, such as opportunistic infections, bone loss, pathological fractures, diabetes, cataracts, and combinations thereof.

[0100] In some embodiments, 15-PGDH inhibitors may be administered to subjects in combination with corticosteroids to treat glucocorticoid insensitivity, restore corticosteroid sensitivity, enhance glucocorticoid sensitivity, and / or reverse glucocorticoid insensitivity in subjects who experience corticosteroid dependence or corticosteroid resistance or refractoriness or intolerance to corticosteroids. Glucocorticoid insensitivity-related conditions may include a range of immune-inflammatory disorders / diseases and combinations thereof that are treated with steroids, where treatment fails to achieve disease suppression or is ineffective or intolerant or dependent on corticosteroids.

[0101] In another embodiment, the 15-PGDH inhibitor and a corticosteroid or the 15-PGDH inhibitor and a TNF inhibitor are used in the treatment of glucocorticoid resistant asthma, refractory rheumatoid arthritis, refractory inflammatory bowel disease, chronic obstructive pulmonary disease, acute respiratory distress syndrome, interstitial pulmonary fibrosis, cystic fibrosis, refractory ulcerative colitis, children with severe Crohn's disease, corticosteroid refractory asthma, corticosteroid refractory desquamative interstitial pneumonia, refractory inflammatory myopathy, refractory myasthenia gravis, refractory pemphigus vulgaris, methotrexate refractory RA patients, refractory nephrotic syndrome, refractory multiple sclerosis, refractory sprue-like disease, steroid resistant sarcoidosis, refractory mucosal lesions of pemphigus vulgaris, refractory Schnitzler syndrome, resistant dermatitis of the head and neck, Neck, severe refractory atopic dermatitis, refractory idiopathic thrombocytopenic purpura, refractory orbital myositis, refractory or recurrent lymphoma, severely ill patients with sepsis or acute respiratory distress syndrome (ARDS) and associated adrenal insufficiency, rosacea, polymyalgia rheumatica, giant cell arteritis, polymyositis, dermatomyositis, Kawasaki syndrome, Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, stiff-man syndrome, corticosteroid-dependent systemic lupus erythematosus, corticosteroid-dependent multiple sclerosis, symptomatic corticosteroid-dependent asthma, primary Sjogren's syndrome, systemic vasculitis, polymyositis, organ transplantation, graft-versus-host disease, inflammatory diseases, autoimmune diseases, hyperproliferative diseases disease, lupus, osteoarthritis, rhinosinusitis, polyarteritis nodosa, Wegener's granulomatosis, giant cell arteritis, allergic rhinitis, urticaria, hereditary angioedema, tendinitis, bursitis, autoimmune chronic active hepatitis, cirrhosis, transplant rejection, psoriasis, dermatitis (dermatitus), malignant tumors, leukemia, myeloma, lymphoma, acute adrenal insufficiency, rheumatic fever, granulomatous disease, immune proliferation / apoptosisproliferation / apotosis), inhibition and regulation of the hypothalamic-pituitary-adrenal (HPA) axis, hypercortisolism, regulation of Th1 / Th2 cytokine balance, chronic kidney disease, spinal cord injury, cerebral edema, thrombocytopenia, Little's syndrome, Addison's disease, autoimmune hemolytic anemia, uveitis, pemphigus vulgaris, nasal polyps, sepsis, bacterial infections, viral infections, rickettsial infections, parasitic infections, type II diabetes, obesity, metabolic syndrome, depression, schizophrenia, mood disorders, Cushing's syndrome, anxiety, sleep disorders, memory and learning enhancement, glucocorticoid-induced glaucoma, atopic dermatitis, drug hypersensitivity reactions, serum sickness, bullous dermatitis herpetiformis), contact dermatitis, exfoliative erythroderma, mycosis fungoides, pemphigus, nonsuppurative thyroiditis, sympathetic ophthalmia, uveitis, ocular inflammatory conditions unresponsive to topical steroids, allergic bronchopulmonary aspergillosis, fulminant or disseminated pulmonary tuberculosis (when used concomitantly with appropriate chemotherapy), hypersensitivity pneumonitis, idiopathic bronchiolitis obliterans with organizing pneumonia, idiopathic eosinophilic pneumonia, idiopathic pulmonary fibrosis, hypoxemia occurring in HIV(+) individuals who are also being treated with appropriate anti-PCP antibiotics. The present invention may be administered to a subject exhibiting one or more diseases, disorders, or conditions associated with glucocorticoid insensitivity selected from the group consisting of Pneumocystis carinii pneumonia (PCP) associated with hypertension, diuresis or remission of proteinuria in idiopathic types of nephrotic syndrome without uremia or nephrotic syndrome due to lupus erythematosus, ankylosing spondylitis, polymyalgia rheumatica, psoriatic arthritis, relapsing polychondritis, trichinellosis with neurological or myocardial invasion, and tuberculous meningitis.

[0102] 15-PGDH inhibitors used in the methods described herein can be identified using an assay in which a putative inhibitor compound is applied to cells expressing 15-PGDH and then the functional effect on 15-PGDH activity is determined. Samples or assays containing 15-PGDH treated with a potential inhibitor are compared to control samples without the inhibitor to determine the extent of the effect. The control sample (not treated with a modulator) is assigned a relative 15-PGDH activity value of 100%. Inhibition of 15-PGDH is achieved when the value of 15-PGDH activity compared to the control is about 80%, optionally 50% or 25%, 10%, 5% or 1%.

[0103] The agent that is tested as an inhibitor of 15-PGDH can be any small chemical molecule or compound. Typically, the test compound will be a small chemical molecule, natural product or peptide. The assay is designed to screen large compound libraries by automating the steps of the assay and providing compounds from any convenient source to the assay that typically runs in parallel (e.g., in a microtiter format on a microtiter plate in a robotic assay).

[0104] In some embodiments, the 15-PGDH inhibitor has the following formula (I): [ka] A compound having the formula: n is 0 to 2; Y 1 , Y 2 and R 1 are the same or different and are hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 1 and Y 2may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2 is H, lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, X 1 and X 2 is independently N or C, where X 1 and / or X 2 If N, then Y 1 and / or Y 2 do not exist, Z 1 is O, S, CR a R b or NR a where R a and R bare independently H or C which is linear, branched or cyclic and unsubstituted or substituted. 1~8 is alkyl, Compounds and their pharma- ceutically acceptable salts may be included.

[0105] Examples of 15-PGDH inhibitors having formula (I) include the following compounds: [ka] and pharma-ceutically acceptable salts thereof.

[0106] In other embodiments, the 15-PGDH inhibitor has the following formula (II): [ka] A compound having the formula: n is 0 to 2; X 4 , X 5 , X 6 and X 7 are independently N or CR c and R 1 , R 6 , R 7 and R c are independently hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 6 and R 7 may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2 is H, lower alkyl group, O, (CH2) n1OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, Z 1 is O, S, CR a R b or NR a where R a and R b are independently H or C which is linear, branched or cyclic and unsubstituted or substituted. 1~8 is alkyl, Compounds and their pharma- ceutically acceptable salts may be included.

[0107] Examples of 15-PGDH inhibitors having formula (II) include the following compounds: [ka] and pharma-ceutically acceptable salts thereof.

[0108] In yet other embodiments, the 15-PGDH inhibitor has the following formula (III) or (IV): [ka] A compound having the formula: n is 0 to 2; X 6 are independently N or CR c and R 1 , R 6 , R 7 and R c are independently hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5-C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O- )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 6 and R 7 may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2 is H, lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, Z 1 is O, S, CR a R b or NRa where R a and R b are independently H or C which is linear, branched or cyclic and unsubstituted or substituted. 1~8 is alkyl, Compounds and their pharma- ceutically acceptable salts may be included.

[0109] In some embodiments, R 1 is a branched or linear alkyl group containing -(CH2)n1CH3 (n1=0-7), [ka] wherein n2=0-6 and X is any of the following: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 ,CN,N(R 73 )2, [ka]

[0110] In other embodiments, R 6 and R 7 may each independently be one of the following: [ka] Each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72 , R 73 and R 74 are the same or different and independently represent hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20aryl, heterocycloalkenyl containing 5 to 6 ring atoms (wherein 1 to 3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), heteroaryl or heterocyclyl containing 5 to 14 ring atoms (wherein 1 to 6 of the ring atoms are independently selected from N, NH, N(C1-C3 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, silyl, hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N -), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), sulfanamide (-SON(R); where R is independently H, alkyl, aryl, or heteroaryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether (-[(CH2) n O] m), phosphate, phosphate ester [-OP(O)(OR)2; where R=H, methyl or other alkyl]; groups incorporating an amino acid or other moiety that is expected to carry a positive or negative charge at physiological pH; and combinations thereof, and pharma- ceutically acceptable salts thereof.

[0111] In yet another embodiment, R 6 and R 7 may independently be a group that improves water solubility (e.g., a phosphate ester (-OPO3H2), a phenyl ring linked to a phosphate ester (-OPO3H2), a phenyl ring substituted with one or more methoxyethoxy groups, or morpholine), or an aryl or heteroaryl ring substituted with such a group.

[0112] Examples of 15-PGDH inhibitors having formula (III) or (IV) include the following compounds: [ka] TIFF0007595413000015.tif99160 and pharma-ceutically acceptable salts thereof.

[0113] In other embodiments, the 15-PGDH inhibitor has the following formula (V): [ka] A compound having the formula: n is 0 to 2; X 6 are independently N or CR c and R 1 , R 6 , R 7 and R c are each independently hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24Alkynyl, C3-C 20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5-C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 6 and R 7may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; U 1 N, CR 2 or C-NR 3 R 4 where R 2 is H, lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, O-CH2-CH2X, CH2-CH2-CH2X, O-CH2-CH2X, X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), O(CO)R', COOR' (where R' is H or a lower alkyl group); R 1 and R 2 may be linked to form a cyclic or polycyclic ring, R 3 and R 4 are the same or different and are H, a lower alkyl group, O, (CH2) n1 OR' (where n1=1, 2, or 3), CF, CH2-CH2X, CH2-CH2-CH2X (where X=H, F, Cl, Br, or I), CN, (C=O)-R', (C=O)N(R'), COOR' (where R' is H or a lower alkyl group), R 3 or R 4 may not be present, Compounds and their pharma- ceutically acceptable salts may be included.

[0114] In some embodiments, R 1 is a branched or linear alkyl group containing -(CH2)n1CH3 (n1=0-7), [ka] wherein n2=0-6 and X is any of the following: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 ,CN,N(R 73 )2, [ka]

[0115] In other embodiments, R 6 and R 7 may each independently be one of the following: [ka] Each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72 , R 73 and R 74 are the same or different and independently represent hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 aryl, heterocycloalkenyl containing 5 to 6 ring atoms (wherein 1 to 3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), heteroaryl or heterocyclyl containing 5 to 14 ring atoms (wherein 1 to 6 of the ring atoms are independently selected from N, NH, N(C1-C3 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, silyl, hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), sulfanamide (-SON(R); where R is independently H, alkyl, aryl, or heteroaryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5-C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether (-[(CH2) n O] m ), phosphate, phosphate ester [-OP(O)(OR)2; where R=H, methyl or other alkyl]; groups incorporating an amino acid or other moiety that is expected to carry a positive or negative charge at physiological pH; and combinations thereof, and pharma- ceutically acceptable salts thereof.

[0116] In yet another embodiment, R 6 and R 7 may independently be a group that improves water solubility (e.g., a phosphate ester (-OPO3H2), a phenyl ring linked to a phosphate ester (-OPO3H2), a phenyl ring substituted with one or more methoxyethoxy groups, or morpholine), or an aryl or heteroaryl ring substituted with such a group.

[0117] In other embodiments, the 15-PGDH inhibitor has the following formula (VI): [ka] A compound having the formula: n=0 to 2, X 6 is N or CR c and R 1 is a branched or linear alkyl group containing -(CH2)n1CH3 (n1=0-7), [ka] wherein n2=0 to 6 and X is selected from the group consisting of: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 ,CN,N(R 73 )2, [ka] is one of R 5 are H, Cl, F, NH2 and N(R 76 ) 2 selected from the group consisting of R 6 and R 7 are each independently one of the following: [ka] may be one of: Each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72 , R 73 , R 74 , R 76 and R c are the same or different and independently represent hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24Alkynyl, C3-C 20 aryl, heterocycloalkenyl containing 5 to 6 ring atoms (wherein 1 to 3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), heteroaryl or heterocyclyl containing 5 to 14 ring atoms (wherein 1 to 6 of the ring atoms are independently selected from N, NH, N(C1-C3 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, silyl, hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N -), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), sulfanamide (-SON(R); where R is independently H, alkyl, aryl, or heteroaryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5-C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether (-[(CH2) n O] m), phosphate, phosphate ester [-OP(O)(OR)2; where R=H, methyl or other alkyl]; groups incorporating an amino acid or other moiety that is expected to carry a positive or negative charge at physiological pH; and combinations thereof. Compounds and their pharma- ceutically acceptable salts may be included.

[0118] In other embodiments, the 15-PGDH inhibitor has the following formula (VII): [ka] A compound having the formula: n=0 to 2, X 6 is N or CR c and R 1 is a branched or linear alkyl group containing -(CH2)n1CH3 (n1=0-7), [ka] wherein n2=0 to 6 and X is selected from the group consisting of: CF y H z (y+z=3), CCl y H z (y+z=3), OH, OAc, OMe, R 71 , OR 72 ,CN,N(R 73 )2, [ka] is one of R 5 are H, Cl, F, NH2 and N(R 76 ) 2 selected from the group consisting of R 7 are each independently one of the following: [ka] may be one of: Each R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 37 , R 38 , R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 61 , R 62 , R 63 , R 64 , R 65 , R 66 , R 67 , R 68 , R 69 , R 70 , R 71 , R 72, R 73 , R 74 , R 76 and R c are the same or different and independently represent hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 aryl, heterocycloalkenyl containing 5 to 6 ring atoms (wherein 1 to 3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), heteroaryl or heterocyclyl containing 5 to 14 ring atoms (wherein 1 to 6 of the ring atoms are independently selected from N, NH, N(C1-C3 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, silyl, hydroxyl, sulfhydryl, C1-C 24 Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), sulfanamide (-SON(R); where R is independently H, alkyl, aryl, or heteroaryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24 aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether (-[(CH2) n O] m ), phosphate, phosphate ester [-OP(O)(OR)2; where R=H, methyl or other alkyl]; groups incorporating an amino acid or other moiety that is expected to carry a positive or negative charge at physiological pH; and combinations thereof. Compounds and their pharma- ceutically acceptable salts may be included.

[0119] Examples of compounds having formula (V), (VI) or (VII) are: [ka] TIFF0007595413000029.tif198161 TIFF0007595413000030.tif155160 TIFF0007595413000031.tif199160 TIFF0007595413000032.tif211160 TIFF0007595413000033.tif208160TIFF0007595413000034.tif192160TIFF0007595413000035.tif172160TIFF0007595413000036.tif18716 1TIFF0007595413000037.tif178160TIFF0007595413000038.tif235160TIFF0007595413000039.tif218160TIFF0007595413000040.tif80160 and pharma- ceutically acceptable salts thereof.

[0120] In certain embodiments, (ia) at a concentration of 2.5 μM, it is capable of stimulating a Vaco503 reporter cell line expressing a 15-PGDH luciferase fusion construct to a luciferase output level of greater than 70 (using a scale where a value of 100 represents a doubling of reporter output over baseline); (iia) at a concentration of 2.5 μM, it is capable of stimulating a V9m reporter cell line expressing a 15-PGDH luciferase fusion construct to a luciferase output level of greater than 75; (iiia) at a concentration of 7.5 μM, it is capable of stimulating a LS174T reporter cell line expressing a 15-PGDH luciferase fusion construct to a luciferase output level of greater than 70; and (iva) at a concentration of 7.5 μM, it does not activate a negative control V9m cell line expressing a TK-Renilla luciferase reporter to a level greater than 20; and (va) has an IC of less than 1 μM. 50 In one embodiment, a 15-PGDH inhibitor having formula (I), (II), (III), (IV), (V), (VI) or (VII) may be selected which inhibits the enzymatic activity of the recombinant 15-PGDH protein in

[0121] In other embodiments, the 15-PGDH inhibitor (ib) is capable of stimulating a Vaco503 reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output at a concentration of 2.5 μM; (iib) is capable of stimulating a V9m reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output at a concentration of 2.5 μM; (iiib) is capable of stimulating a LS174T reporter cell line expressing a 15-PGDH luciferase fusion construct to increase luciferase output at a concentration of 7.5 μM; (ivb) does not activate a negative control V9m cell line expressing a TK-Renilla luciferase reporter to luciferase levels more than 20% above background at a concentration of 7.5 μM; and (vb) has an IC of less than 1 μM. 50inhibits the enzymatic activity of recombinant 15-PGDH protein.

[0122] In other embodiments, the 15-PGDH inhibitor has an IC of less than 1 μM at a recombinant 15-PGDH concentration of about 5 nM to about 10 nM. 50 or preferably an IC of less than 250 nM 50 or more preferably an IC of less than 50 nM 50 or more preferably an IC of less than 10 nM 50 or more preferably an IC of less than 5 nM 50 and can inhibit the enzyme activity of recombinant 15-PGDH.

[0123] In other embodiments, 15-PGDH inhibitors are capable of increasing cellular levels of PGE-2 following stimulation of A459 cells with an appropriate agent (eg, IL1β).

[0124] In some embodiments, the 15-PGDH inhibitor has the following formula (VIII): [ka] A compound having the formula: n is 0 to 2; R 1 , R 6 and R 7 are the same or different and are hydrogen, substituted or unsubstituted C1-C 24 Alkyl, C2-C 24 Alkenyl, C2-C 24 Alkynyl, C3-C 20 Aryl, heteroaryl, heterocycloalkenyl containing 5-6 ring atoms (wherein 1-3 of the ring atoms are independently selected from N, NH, N(C1-C6 alkyl), NC(O)(C1-C6 alkyl), O, and S), C6-C 24 Alkaryl, C6~C 24 Aralkyl, halo, -Si(C1-C3 alkyl), hydroxyl, sulfhydryl, C1-C 24Alkoxy, C2-C 24 Alkenyloxy, C2-C 24 Alkynyloxy, C5-C 20 Aryloxy, acyl (C2-C 24 Alkylcarbonyl (-CO-alkyl) and C6-C 20 Arylcarbonyl (-CO-aryl) is included), acyloxy (-O-acyl), C2-C 24 Alkoxycarbonyl (-(CO)-O-alkyl), C6-C 20 Aryloxycarbonyl (-(CO)-O-aryl), C2-C 24 Alkylcarbonate (-O-(CO)-O-alkyl), C6-C 20 Arylcarbonato (-O-(CO)-O-aryl), carboxy (-COOH), carboxylato (-COO - ), Carbamoyl (-(CO)-NH2), C1-C 24 Alkyl-carbamoyl (-(CO)-NH(C1-C 24 alkyl), arylcarbamoyl (-(CO)-NH-aryl), thiocarbamoyl (-(CS)-NH2), carbamide (-NH-(CO)-NH2), cyano (-CN), isocyano (-N + C - ), cyanate (-O-CN), isocyanate (-ON + =C - ), isothiocyanato (-S-CN), azido (-N=N + =N - ), formyl (-(CO)-H), thioformyl (-(CS)-H), amino (-NH2), C1-C 24 Alkylamino, C5-C 20 Arylamino, C2-C 24 Alkylamide (-NH(CO)-alkyl), C6~C 20 Arylamide (-NH(CO)-aryl), imino (-CR=NH; where R is hydrogen, C1-C 24 Alkyl, C5-C 20 Aryl, C6-C 24 Alkaryl, C6~C 24aralkyl, etc.), alkylimino (-CR=N(alkyl); where R=hydrogen, alkyl, aryl, alkaryl, aralkyl, etc.), arylimino (-CR=N(aryl); where R=hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO2), nitroso (-NO), sulfo (-SO2-OH), sulfonato (-SO2-O - ), C1~C 24 Alkylsulfanyl (-S-alkyl; also called "alkylthio"), arylsulfanyl (-S-aryl; also called "arylthio"), C1-C 24 Alkylsulfinyl (-(SO)-alkyl), C5-C 20 Arylsulfinyl (-(SO)-aryl), C1-C 24 Alkylsulfonyl (-SO2-alkyl), C5~C 20 Arylsulfonyl (-SO2-aryl), sulfonamide (-SO2-NH2, -SO2NY2 (where Y is independently H, aryl or alkyl)), phosphono (-P(O)(OH)2), phosphonato (-P(O)(O - )2), phosphinato (-P(O)(O - )), phospho (-PO2), phosphino (-PH2), polyalkyl ether, phosphate, phosphate ester; groups incorporating amino acids or other moieties that are predicted to carry a positive or negative charge at physiological pH; and combinations thereof; 6 and R 7 may be linked to form a cyclic or polycyclic ring, where the ring is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, and substituted or unsubstituted heterocyclyl; Compounds and their pharma- ceutically acceptable salts may be included.

[0125] The 15-PGDH inhibitors having the formula (VIII) can be synthesized as shown below: [ka]

[0126] Any reaction solvent may be used in the above preparation process, as long as it does not participate in the reaction. For example, the reaction solvent includes ethers (such as diethyl ether, tetrahydrofuran and dioxane); halogenated hydrocarbons (such as dichloromethane and chloroform); amines (such as pyridine, piperidine and triethylamine); alkyl ketones (such as acetone, methyl ethyl ketone and methyl isobutyl); alcohols (such as methanol, ethanol and propanol); aprotic polar solvents (such as N,N-dimethylformamide, N,N-dimethylacetamide, acetonitrile, dimethyl sulfoxide and hexamethylphosphoric acid triamide). Among the non-reactive organic solvents commonly used in organic synthesis, preferred solvents are those that can remove the water generated in the reaction by Dean-Stark trap. Examples of such solvents include, but are not limited to, benzene, toluene, xylene, and the like. The reaction product thus obtained may be isolated and purified by condensation, extraction, and the like, which are commonly performed in the field of organic synthesis, and by silica gel column chromatography, if desired. The individual enantiomers of the PGDH inhibitor having formula III can be separated by preparative HPLC using a chromatography column containing a chiral stationary phase.

[0127] Furthermore, the embodiments of the present application include any modification of the above-mentioned preparation method of 15-PGDH inhibitor. In this regard, any intermediate product that can be obtained from any step of the preparation method can be used as starting material in other steps. Such starting material can be formed in situ under certain reaction conditions. Reactive reagents can also be used in the form of their salts or optical isomers.

[0128] Depending on the type of substituents used in the preparation of the 15-PGDH inhibitors, as well as the intermediate products and the preparation methods selected, the novel 15-PGDH inhibitors may be in the form of any of the possible isomers, such as substantially pure geometric (cis or trans) isomers, optical isomers (enantiomers) and racemates.

[0129] In some embodiments, the 15-PGDH inhibitor having formula (VIII) has the following formula (IX): [ka] and pharma- ceutically acceptable salts thereof.

[0130] Advantageously, 15-PGDH inhibitors having formula (IX) have been found to (i) inhibit recombinant 15-PGDH at a concentration of 1 nM; (ii) inhibit 15-PGDH in cell lines at a concentration of 100 nM; (iii) increase PGE2 production by cell lines; (iv) be chemically stable in aqueous solution over a wide pH range; (v) be chemically stable when incubated with hepatocyte extracts; (vi) be chemically stable when incubated with hepatocyte cell lines; (vii) exhibit a plasma half-life of 253 minutes when injected IP in mice; and (viii) show no immediate toxicity when injected IP in mice at 0.6 μmol per mouse and 1.2 μmol per mouse over a 24 hour period, and no toxicity when injected IP in mice at 0.3 μmol per mouse twice daily for 21 days.

[0131] In another embodiment, the 15-PGDH inhibitor having formula (IX) has the following formula (IXa): [ka] and pharma- ceutically acceptable salts thereof.

[0132] In yet another embodiment, the 15-PGDH inhibitor having formula (IX) has the following formula (IXb): [ka] and pharma- ceutically acceptable salts thereof.

[0133] In other embodiments, the 15-PGDH inhibitor may comprise either the (+) or (-) optical isomer of the 15-PGDH inhibitor having the formula (IX). In yet other embodiments, the 15-PGDH inhibitor may comprise a mixture of at least one of the (+) or (-) optical isomers of the 15-PGDH inhibitor having the formula (IX). For example, the 15-PGDH inhibitor may be one having less than about 50% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (IX) and more than about 50% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (IX); less than about 25% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (IX) and more than about 75% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (IX); less than about 10% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (IX) and more than about 90% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (IX); less than about 1% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (IX) and more than about 99% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (IX). % of the (-) enantiomer of 15-PGDH inhibitor having formula (IX) and less than about 50% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (IX), greater than about 75% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (IX) and less than about 25% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (IX), greater than about 90% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (IX) and less than about 10% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (IX), or greater than about 99% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (IX) and less than about 1% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (IX).

[0134] In yet another embodiment, the 15-PGDH inhibitor may consist essentially of or consist of the (+) enantiomer of the 15-PGDH inhibitor having formula (IX). In yet another embodiment, the 15-PGDH inhibitor may consist essentially of or consist of the (-) enantiomer of the 15-PGDH inhibitor having formula (IX).

[0135] In another embodiment, the 15-PGDH inhibitor having formula (VIII) has the following formula (X): [ka] and pharma- ceutically acceptable salts thereof.

[0136] Advantageously, the 15-PGDH inhibitor having formula (X) was found to (i) inhibit recombinant 15-PGDH at a concentration of 3 nM; (ii) increase PGE2 production by cell lines at 20 nM; (iii) be chemically stable in aqueous solution over a wide pH range; (iv) be chemically stable when incubated with mouse, rat and human liver extracts; (v) exhibit a plasma half-life of 33 minutes when injected IP in mice; (viii) show no immediate toxicity over 24 hours when injected IP in mice at 50 mg / kg body weight; and (ix) be soluble in water (pH=3) at 1 mg / mL.

[0137] In other embodiments, the 15-PGDH inhibitor having the formula (X) has the following formula (Xa): [ka] and pharma- ceutically acceptable salts thereof.

[0138] In yet another embodiment, the 15-PGDH inhibitor having the formula (X) has the following formula (Xb): [ka] and pharma- ceutically acceptable salts thereof.

[0139] In other embodiments, the 15-PGDH inhibitor may comprise either the (+) or (-) optical isomer of the 15-PGDH inhibitor having the formula (X). In yet other embodiments, the 15-PGDH inhibitor may comprise a mixture of at least one of the (+) or (-) optical isomers of the 15-PGDH inhibitor having the formula (X). For example, the 15-PGDH inhibitor may be one having less than about 50% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (X) and more than about 50% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (X); less than about 25% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (X) and more than about 75% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (X); less than about 10% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (X) and more than about 90% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (X); less than about 1% by weight of the (-) enantiomer of the 15-PGDH inhibitor having formula (X) and more than about 99% by weight of the (+) enantiomer of the 15-PGDH inhibitor having formula (X). % by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (X) and less than about 50% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (X), greater than about 75% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (X) and less than about 25% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (X), greater than about 90% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (X) and less than about 10% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (X), or greater than about 99% by weight of the (-) enantiomer of 15-PGDH inhibitor having formula (X) and less than about 1% by weight of the (+) enantiomer of 15-PGDH inhibitor having formula (X).

[0140] In yet another embodiment, the 15-PGDH inhibitor may consist essentially of, or consist of, the (+) enantiomer of the 15-PGDH inhibitor having the formula (X). In yet another embodiment, the 15-PGDH inhibitor may consist essentially of, or consist of, the (-) enantiomer of the 15-PGDH inhibitor having the formula (X).

[0141] It will be understood that other 15-PGDH inhibitors may be used in the methods described herein.These other 15-PGDH inhibitors may include known 15-PGDH inhibitors, such as the tetrazole compounds of formula (I) and (II), the 2-alkylidene aminooxyacetamide compounds of formula (I), the heterocyclic compounds of formula (VI) and (VII), and the pyrazole compounds of formula (III) described in U.S. Patent Application Publication No. 2006 / 0034786 and U.S. Patent No. 7,705,041; the benzylidene-1,3-thiazolidine compounds of formula (I) described in U.S. Patent Application Publication No. 2007 / 0071699; the benzylidene-1,3-thiazolidine compounds of formula (I) described in U.S. Patent Application Publication No. 2007 / 0078175; No. 2011 / 0269954; thiazolidenedione derivatives described in U.S. Patent Application Publication No. 2011 / 0269954; phenylfuran compounds, phenylthiophene compounds, or phenylpyrazole compounds described in U.S. Patent No. 7,294,641; 5-(3,5-disubstituted phenylazo)-2-hydroxybenzene-acetic acids and salts and lactones described in U.S. Patent No. 4,725,676; and azo compounds described in U.S. Patent No. 4,889,846.

[0142] In certain embodiments, the corticosteroid is selected from the group consisting of aclobate, alclometasone dipropionate, amcinafel, amcinafide, amcinonide, aristocort A, enhanced betamethasone dipropionate, beclamethasone, beclometasone dipropionate, betamethasone, betamethasone benzoate, betamethasone-17-benzoate, betamethasone dipropionate, betamethasone acetate-betamethasone sodium phosphate, betamethasone valerate, betamethasone-17-valerate, chloroprednisone, clobetasol propionate ... Betasone, Clocortelone, Cordran, Corticosterone, Cortisol, Cortisol Acetate, Cortisol Cypionate, Cortisol Sodium Phosphate, Cortisol Sodium Succinate, Cortisone, Cortisone Acetate, Cortodoxone, Cyclocort, Deflazacort, Defulprednate, Descinolone, Desonide, Desowen, Desoxymethasone, Desoxycorticosterone Acetate, Desoxycorticosterone Pivalate, 11-Desoxycortisol, Dexamethasone, Dexamethasone Acetate, Dexamethasone Sodium Phosphate, Dichloriso diflorasone diacetate, dihydroxycortisone, diprolen, diprolene, diprosone, betamethasone ester, fluronide, flucetonide, flucloronide, flucortolone, fludrocortisone, fludrocortisone acetate, flumethalone, flumethasone, flumethasone pivalate, flunisolide, fluocinolone acetonide, fluocinolone acetonide acetate, fluocinonide, fluorametholone, fluorocortisone, fluperolone, fluprednisolone, flurandrenolide, fluroandrenolone a Setonide, fluticasone propionate, fuprednisolone, halcinonide, halobetasol propionate, Halog, hydrocortamate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, hydrocortisone-17-valerate, Kenalog, Lidex, Locord, Locorten, Maxiflor, medrysone, meprednisone, methylprednisolone, 6α-methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisone, mometasone furoate, paramethasone,Selected from the group consisting of paramethasone acetate, prednidone, prednisone, prednisolone, prednisolone acetate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone tebutate, prednisone, psolcon, sinaral, temovate, tetrahydrocortisol, topicort, topicort LP, triamcinolone, triamcinolone acetonide, triamcinolone diacetate, triamcinolone hexacotonide, tridecylone, varisone and westcoat.

[0143] In other embodiments, the corticosteroid used in combination with the 15-PGDH inhibitors described herein is prednisolone, methylprednisolone, dexamethasone, naflocort, deflazacort, halopredone acetate, budesonide, beclomethasone dipropionate, hydrocortisone, triamcinolone acetonide, fluocinolone acetonide, fluocinonide, clocortolone pivalate, methylprednisolone aceponate, dexamethasone palmitoate, tipredane, hydrocortisone aceponate, prednicarbate, alclometasone dipropionate, halometasone, methylprednisolone suleptanate, mometasone furoate, rimexolone, prednisolone famesilate. famesylate), ciclesonide, deprodone propionate, fluticasone, fluticasone propionate, fluticasone furoate, halobetasol propionate, loteprednol etabonate, betamethasone butyrate propionate, flunisolide, prednisone, dexamethasone sodium phosphate, triamcinolone, betamethasone 17-valerate, betamethasone, hydrocortisone acetate, hydrocortisone sodium succinate, prednisolone sodium phosphate, and hydrocortisone probutate.

[0144] In certain embodiments, TNF inhibitors described herein may include, but are not limited to, anti-TNFα antibodies (such as infliximab, adalimumab, certolizumab pegol and / or golimumab), receptor-construct fusion proteins (such as etanercept), or small molecules (such as, but not limited to, pomalidomide, thalidomide, lenalidomide and bupropion).

[0145] The 15-PGDH inhibitors and corticosteroids and TNF inhibitors described herein may be provided in a pharmaceutical composition. Pharmaceutical compositions containing the 15-PGDH inhibitors and corticosteroids described herein as active ingredients may be prepared by mixing the derivatives with a pharma- ceutically acceptable carrier(s) or excipient(s) or diluting the 15-PGDH inhibitors and corticosteroids and TNF inhibitors described herein with a diluent according to conventional methods. The pharmaceutical composition may further include fillers, anti-cohesives, lubricants, wetting agents, flavorings, emulsifiers, preservatives, and the like. The pharmaceutical composition may be formulated into a suitable formulation according to methods known to those skilled in the art so that it can provide immediate, controlled or sustained release of the 15-PGDH inhibitors and / or corticosteroids described herein after administration to a mammal.

[0146] In some embodiments, the pharmaceutical composition may be formulated into a parenteral or oral dosage form. The solid dosage form for oral administration may be prepared by adding an excipient (with binder, disintegrant, lubricant, colorant and / or flavorant, if necessary) to the 15-PGDH inhibitor and corticosteroid described herein, and shaping the resulting mixture into the form of a tablet, dragee, granule, powder or capsule. The additives that can be added to the composition may be those that are conventional in the art. For example, examples of excipients include lactose, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, silicate, etc. Exemplary binders include water, ethanol, propanol, sweet syrup, sucrose solution, starch solution, gelatin solution, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylstarch, methylcellulose, ethylcellulose, shellac, calcium phosphonate and polypyrrolidone. Examples of disintegrants include dry starch, sodium alginate, agar powder, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, monoglyceride stearate and lactose.Furthermore, refined talc, stearic acid salts, sodium borate and polyethylene glycol may be used as lubricants, and sucrose, bitter orange peel, citric acid, tartaric acid may be used as flavorings.In some embodiments, pharmaceutical compositions can be made into aerosol preparations (e.g., they can be nebulized) for administration by inhalation.

[0147] The 15-PGDH inhibitors and corticosteroids described herein may be combined with flavorings, buffers, stabilizers, etc., and incorporated into oral liquid dosage forms such as solutions, syrups, or elixirs according to conventional methods. An example of a buffer may be sodium citrate. Examples of stabilizers include tragacanth, acacia, and gelatin.

[0148] In some embodiments, the 15-PGDH inhibitors and corticosteroids described herein may be incorporated into an injectable dosage form, for example for subcutaneous, intramuscular or intravenous routes, by adding pH adjusters, buffers, stabilizers, relaxants, local anesthetics thereto. Examples of pH adjusters and buffers include sodium citrate, sodium acetate and sodium phosphate. Examples of stabilizers include sodium pyrosulfite, EDTA, thioglycolic acid and thiolactic acid. Local anesthetics may be procaine HCl, lidocaine HCl, etc. Relaxants may be sodium chloride, glucose, etc.

[0149] In other embodiments, the 15-PGDH inhibitors and corticosteroids described herein may be incorporated into suppositories in a conventional manner by adding thereto a pharma- ceutically acceptable carrier known in the art (e.g., polyethylene glycol, lanolin, cocoa butter, or fatty acid triglycerides) (with a surfactant, such as Tween, if desired).

[0150] The pharmaceutical compositions may be formulated into various dosage forms as described above and then administered by various routes including oral, inhalation, transdermal, subcutaneous, intravenous or intramuscular. The dosage may be a medicamentously or therapeutically effective amount.

[0151] The therapeutically effective dosages of the 15-PGDH inhibitors and corticosteroids described herein may be present in different amounts in various embodiments. For example, in some embodiments, the therapeutically effective amount of the 15-PGDH inhibitor is about 10-1000 mg (e.g., about 20 mg-1,000 mg, 30 mg-1,000 mg, 40 mg-1,000 mg, 50 mg-1,000 mg, 60 mg-1,000 mg, 70 mg-1,000 mg, 80 mg-1,000 mg, 90 mg-1,000 mg, about 10-900 mg, 10-800 mg, 10-700 mg, 10-600 mg, 10-500 mg, 100-1000 mg, 100-900 mg, 100-800 mg, 100-700 mg, 100-600 mg, 10 ...200 mg, 100-200 mg, 100-300 mg, 100-400 mg, 100-500 mg, 100-600 mg, 100-700 mg, 100-800 mg, 100-900 mg, 100-800 mg, 1 The amount may be in the range of 100 mg to 400 mg, 100 mg to 300 mg, 200 mg to 1000 mg, 200 mg to 900 mg, 200 mg to 800 mg, 200 mg to 700 mg, 200 mg to 600 mg, 200 mg to 500 mg, 200 mg to 400 mg, 300 mg to 1000 mg, 300 mg to 900 mg, 300 mg to 800 mg, 300 mg to 700 mg, 300 mg to 600 mg, 300 mg to 500 mg, 400 mg to 1,000 mg, 500 mg to 1,000 mg, 100 mg to 900 mg, 200 mg to 800 mg, 300 mg to 700 mg, 400 mg to 700 mg, and 500 mg to 600 mg. In some embodiments, the 15-PGDH inhibitor is present in an amount of about 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg or more. In some embodiments, the 15-PGDH inhibitor is present in an amount of about 1000 mg, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, or 100 mg or less.

[0152] In other embodiments, the therapeutically effective amount of a corticosteroid is about 10-1000 mg (e.g., about 20 mg-1,000 mg, 30 mg-1,000 mg, 40 mg-1,000 mg, 50 mg-1,000 mg, 60 mg-1,000 mg, 70 mg-1,000 mg, 80 mg-1,000 mg, 90 mg-1,000 mg, about 10-900 mg, 10-800 mg, 10-700 mg, 10-600 mg, 10-500 mg, 100-1000 mg, 100-900 mg, 100-800 mg, 100-700 mg, 100-600 mg, 100-500 mg, The amount may be in the range of 00-400mg, 100-300mg, 200-1000mg, 200-900mg, 200-800mg, 200-700mg, 200-600mg, 200-500mg, 200-400mg, 300-1000mg, 300-900mg, 300-800mg, 300-700mg, 300-600mg, 300-500mg, 400mg-1,000mg, 500mg-1,000mg, 100mg-900mg, 200mg-800mg, 300mg-700mg, 400mg-700mg, and 500mg-600mg). In some embodiments, the corticosteroid is present in an amount of about 10 mg, 50 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg or more. In some embodiments, the corticosteroid is present in an amount of about 1000 mg, 950 mg, 900 mg, 850 mg, 800 mg, 750 mg, 700 mg, 650 mg, 600 mg, 550 mg, 500 mg, 450 mg, 400 mg, 350 mg, 300 mg, 250 mg, 200 mg, 150 mg, or 100 mg or less.

[0153] In other embodiments, a therapeutically effective dosage of a 15-PGDH inhibitor and / or a corticosteroid may be, for example, about 0.001 mg / kg body weight to 500 mg / kg body weight (e.g., about 0.001 mg / kg body weight to 400 mg / kg body weight, about 0.001 mg / kg body weight to 300 mg / kg body weight, about 0.001 mg / kg body weight to 200 mg / kg body weight, about 0.001 mg / kg body weight to 100 mg / kg body weight, about 0.001 mg / kg body weight to 90 mg / kg body weight, about 0.001 mg / kg body weight to 80 mg / kg body weight). body weight, about 0.001 mg / kg body weight to 70 mg / kg body weight, about 0.001 mg / kg body weight to 60 mg / kg body weight, about 0.001 mg / kg body weight to 50 mg / kg body weight, about 0.001 mg / kg body weight to 40 mg / kg body weight, about 0.001 mg / kg body weight to 30 mg / kg body weight, about 0.001 mg / kg body weight to 25 mg / kg body weight, about 0.001 mg / kg body weight to 20 mg / kg body weight, about 0.001 mg / kg body weight to 15 mg / kg body weight, about 0.001 mg / kg body weight to 10 mg / kg body weight).

[0154] In yet other embodiments, a therapeutically effective dosage of a 15-PGDH inhibitor and / or a corticosteroid may be, for example, about 0.0001 mg / kg body weight to 0.1 mg / kg body weight (e.g., about 0.0001 mg / kg body weight to 0.09 mg / kg body weight, about 0.0001 mg / kg body weight to 0.08 mg / kg body weight, about 0.0001 mg / kg body weight to 0.07 mg / kg body weight, about 0.0001 mg / kg body weight to 0.06 mg / kg body weight, about 0.0001 mg / kg body weight to 0.06 mg / kg body weight, about 0.0001 mg / kg body weight to 0.07 ... kg body weight to 0.05mg / kg body weight, about 0.0001mg / kg body weight to about 0.04mg / kg body weight, about 0.0001mg / kg body weight to 0.03mg / kg body weight, about 0.0001mg / kg body weight to 0.02mg / kg body weight, about 0.0001mg / kg body weight to 0.019mg / kg body weight, about 0.0001mg / kg body weight to 0.018mg / kg body weight, about 0.0001mg / kg body weight to 0.017mg / kg body weight, about 0.0001mg / kg body weight to 0.016mg / kg body weight mg / kg body weight, about 0.0001mg / kg body weight to 0.015mg / kg body weight, about 0.0001mg / kg body weight to 0.014mg / kg body weight, about 0.0001mg / kg body weight to 0.013mg / kg body weight, about 0.0001mg / kg body weight to 0.012mg / kg body weight, about 0.0001mg / kg body weight to 0.011mg / kg body weight, about 0.0001mg / kg body weight to 0.01mg / kg body weight, about 0.0001mg / kg body weight to 0.009mg / kg body weight, about 0.0001 mg / kg body weight to 0.008 mg / kg body weight, about 0.0001 mg / kg body weight to 0.007 mg / kg body weight, about 0.0001 mg / kg body weight to 0.006 mg / kg body weight, about 0.0001 mg / kg body weight to 0.005 mg / kg body weight, about 0.0001 mg / kg body weight to 0.004 mg / kg body weight, about 0.0001 mg / kg body weight to 0.003 mg / kg body weight, about 0.0001 mg / kg body weight to 0.002 mg / kg body weight).In some embodiments, a therapeutically effective dose is 0.0001 mg / kg body weight, 0.0002 mg / kg body weight, 0.0003 mg / kg body weight, 0.0004 mg / kg body weight, 0.0005 mg / kg body weight, 0.0006 mg / kg body weight, 0.0007 mg / kg body weight, 0.0008 mg / kg body weight, 0.0009 mg / kg body weight, 0.001 mg / kg body weight, 0.002 mg / kg body weight, 0.003 mg / kg body weight, 0. ... g body weight, 0.005 mg / kg body weight, 0.006 mg / kg body weight, 0.007 mg / kg body weight, 0.008 mg / kg body weight, 0.009 mg / kg body weight, 0.01 mg / kg body weight, 0.02 mg / kg body weight, 0.03 mg / kg body weight, 0.04 mg / kg body weight, 0.05 mg / kg body weight, 0.06 mg / kg body weight, 0.07 mg / kg body weight, 0.08 mg / kg body weight, 0.09 mg / kg body weight or 0.1 mg / kg body weight. The effective dose for a particular individual may vary (e.g., increase or decrease) over time, depending on the needs of that individual.

[0155] In some embodiments, the therapeutically effective dosage of a 15-PGDH inhibitor and / or a corticosteroid may be a dosage of 10 μg / kg / day, 50 μg / kg / day, 100 μg / kg / day, 250 μg / kg / day, 500 μg / kg / day, or 1000 μg / kg / day or more. In various embodiments, the amount of 15-PGDH inhibitor and / or corticosteroid is sufficient to provide a dosage in the patient of between 0.01 μg / kg and 10 μg / kg, between 0.1 μg / kg and 5 μg / kg, between 0.1 μg / kg and 1000 μg / kg, between 0.1 μg / kg and 900 μg / kg, between 0.1 μg / kg and 900 μg / kg, between 0.1 μg / kg and 800 μg / kg, between 0.1 μg / kg and 700 μg / kg, between 0.1 μg / kg and 600 μg / kg, between 0.1 μg / kg and 500 μg / kg, or between 0.1 μg / kg and 400 μg / kg.

[0156] The specific dose or amount administered according to the present invention may vary, for example, depending on the nature and / or extent of the desired result, the details of the route and / or timing of administration, and / or one or more characteristics (e.g., body weight, age, personal history, genetic characteristics, lifestyle parameters, severity of cardiac defect and / or level of risk of cardiac defect, etc., or combinations thereof). Such dose or amount can be determined by one of skill in the art. In some embodiments, the appropriate dose or amount is determined according to standard clinical techniques. For example, in some embodiments, the appropriate dose or amount is a dose or amount sufficient to reduce the Disease Severity Index by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100% or more. For example, in some embodiments, an appropriate dose or amount is one that is sufficient to reduce the Disease Severity Index by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100%. Alternatively, or in addition, in some embodiments, an appropriate dose or amount is determined using one or more in vitro or in vivo assays to help identify desirable or optimal dosage ranges or amounts to be administered.

[0157] Various embodiments may include different dosing schedules. In some embodiments, the 15-PGDH inhibitor and the corticosteroid described herein may be administered by continuous infusion. In some embodiments, the continuous infusion is intravenous continuous infusion. In other embodiments, the continuous infusion is subcutaneous continuous infusion. Alternatively, or in addition, in some embodiments, the 15-PGDH inhibitor may be administered once every two months, monthly, twice a month, once every three weeks, once every two weeks, weekly, twice a week, three times a week, daily, twice a day, or another clinically desirable dosing schedule. The dosing schedule for a single subject does not have to be at regular intervals, but may vary over time depending on the needs of the subject.

[0158] For topical administration, the composition may be administered in the form of an aqueous, alcoholic, aqueous-alcoholic or oily solution or suspension; or in the form of a dispersion of the type of lotion or serum; in the form of an emulsion or multiple emulsion, obtained by dispersing a fatty phase in an aqueous phase (O / W) or vice versa (W / O), having a liquid or semi-liquid consistency or in the form of a paste; in the form of a free or compressed powder, to be used as such or incorporated in a physiologically acceptable medium; or in the form of microcapsules or microparticles; or in the form of a vesicular dispersion of ionic and / or non-ionic type. The composition may thus be in the form of a salve, tincture, milk, cream, ointment, powder, patch, impregnated pad, solution, emulsion or vesicular dispersion, lotion, aqueous or anhydrous gel, spray, suspension, shampoo, aerosol or foam. The composition may be anhydrous or aqueous. The composition may also comprise solid preparations constituting soaps or cleansing cakes.

[0159] The pharmaceutical compositions comprising a 15-PGDH inhibitor and a corticosteroid as described herein may further comprise at least one compound selected from, for example, prostaglandins, in particular prostaglandins PGE1, PGE2, their salts, their esters, their analogues and their derivatives, in particular those described in WO98 / 33497, WO95 / 11003, JP97-100091, JP96-134242, in particular agonists of prostaglandin receptors. In particular, the pharmaceutical compositions may comprise prostaglandin F 2α receptor agonists (in acid form or in the form of precursors, especially in ester form) (e.g. latanoprost, fluprostenol, cloprostenol, bimatoprost, unoprostone, etc.), prostaglandin E2 receptor agonists (and their precursors, especially esters, such as travoprost) (17-phenyl PGE2, biprostol, butaprostol, misoprostol, sulprostone, 16,16-dimethyl PGE2, 11-deoxy PGE1, 1-deoxy PGE1, etc.), prostacyclin (IP) receptor agonists and their precursors, especially esters (cicaprost, iloprost, isocarbacycline, beraprost, eprostenol, treprostinil, etc.), prostaglandins D2 receptor agonists and their precursors (especially esters) (BW245C ((4S)-(3-[(3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid), BW246C ((4R)-(3-[(3R,S)-3-cyclohexyl-3-isopropyl]-2,5-dioxo)-4-imidazolidineheptanoic acid), etc.), It may comprise at least one compound such as agonists of the receptor for thromboxane A2 (TP) and their precursors (especially esters), such as I-BOP ([1S-[1a,2a(Z),3b(1E,3S),4a]]-7-[3-[3-hydroxy-4-[4-(iodophenoxy)-1-butenyl]-7-oxabicyclo-[2.2.1]hept-2-yl]-5-heptenoic acid).

[0160] Advantageously, the composition comprises at least one 15-PGDH inhibitor and a corticosteroid as defined above, and a series 2 prostaglandin, in particular PGF 2, for example in saline form or in the form of a precursor, in particular in the form of an ester, for example the isopropyl ester. 2α and PGE2), their derivatives (16,16-dimethyl PGE2, 17-phenyl PGE2 and 16,16-dimethyl PGF 2α , 17-phenyl PGF 2α and the like), a series 1 prostaglandin (11-deoxyprostaglandin E1, 1-deoxyprostaglandin E1, etc.) in saline or ester form, an analogue thereof (in particular latanoprost, travoprost, fluprostenol, unoprostone, bimatoprost, cloprostenol, biprostol, butaprost, misoprostol, a salt thereof or an ester thereof), or at least one prostaglandin or one prostaglandin derivative.

[0161] The present invention is further illustrated by the following examples, which are not intended to limit the scope of the claims. EXAMPLES

[0162] Example 1 Analysis of the effects of SW033291 on dextran sulfate sodium (DSS)-induced colitis This example presents data from a study of the effect of SW033291 on preventing the induction of colitis in mice treated with dextran sulfate sodium (DSS). In this study, 8-12 week old FVB male mice were fed 2% DSS in drinking water on days 1-7, then switched to regular drinking water on day 8 and continued through day 22. Mice were treated twice daily with SW033291 at 125 μg / 200 μl (5 mg / kg IP) in a vehicle of 10% ethanol, 5% Cremophor EL, 85% D5W, or with vehicle alone. Clinical scores (body weight, rectal bleeding, stool consistency) were recorded daily, and endoscopic scores (number of ulcers, mucosal thickening, and vascular pattern) were assessed on days 8, 11, and 15. Mice were sacrificed on days 1, 8, 15 and 22 for assessment of colon length, colon weight, number of ulcers, ulcer area and crypt damage.

[0163] Table 1 provides an overview of the baseline characteristics of age and weight for the 24 SW033291-treated and 24 control mice used in the study. Also presented are the baseline characteristics of four FVB male 15-PGDH knockout (KO) mice used as a comparison group. [Table 1]

[0164] Figure 1 shows a graph of the mean change from baseline body weight for the cohorts of control and SW033291-treated mice over the 22 day period of the study. SW033291-treated mice (squares) exhibited higher body weights than control mice (diamonds) at all time points, and in particular, exhibited faster weight gain than control mice (diamonds) following washout of DSS (P=0.001).

[0165] Figure 2 shows a graph of the daily Disease Activity Index (DAI) for a cohort of control (diamonds) and SW033291-treated mice (squares) over the 22 days of the study. Disease Activity Index was calculated as an equally weighted average of change from baseline body weight, stool consistency and presence of rectal bleeding, with each component normalized to span the same range of values. SW033291-treated mice (squares) show a lower Disease Activity Index than controls (diamonds) on each day of the study (P<0.001).

[0166] Figure 3 shows the study design, where colonoscopy of the left colon (up to the splenic flexure) was performed under isoflurane anesthesia on live mice on days 8, 11, and 15. Daily body weights of these SW033291-treated (squares) and untreated (diamonds) mice were also recorded and shown. Furthermore, postmortem colonoscopy of the whole colon was performed on day 15 on two SW033291-treated (squares) and two control-treated (diamonds) mice, confirming that DSS-induced ulceration was primarily restricted to the descending colon distal to the splenic flexure.

[0167] Figure 4 (A-B) shows the colon visualized during colonoscopy of a DSS-treated control mouse showing loss of mucosal vascular pattern and gross ulceration (bottom left) (Figure 4B). Shown on the bottom right is a colonoscopic view of a DSS-treated mouse fed SW033291, with only small ulcers and otherwise maintaining normal mucosal vascular pattern (Figure 4B). Figure 4A is a graph showing the number of ulcers present on days 8 (bottom), 11 (middle) and 15 (top) in control and SW033291-treated mice. SW033291 treatment prevents two-thirds of ulcer formation. Further studies of 15-PGDH knockout mice show that knockout of the 15-PGDH gene prevents 95% of colonic ulcer formation. These findings confirm that the colitis-preventing activity of SW033291 is mediated through its activity as a 15-PGDH inhibitor and suggest that further modifications of drug administration and delivery may result in further prevention of colitis as well as protection from other forms of intestinal injury, which may include radiation toxicity, chemotherapy toxicity, and chemotherapy-induced mucositis.

[0168] Figure 5 shows quantification of ulcer burden in DSS-treated mice at day 15, determined by embedding full-length formalin-fixed mouse colons in paraffin blocks followed by microscopic examination of random 5 μm sections along the entire length of the colon for visualization and measurement of ulcerated mucosa. The graph shows that the average length of ulcerated mucosa was 4.48 mm per colon section in control mice (N=9 mice) and was reduced by 61% (P=0.045) to a length of 1.74 mm per colon section in SW033291 (drug)-treated mice (N=6 mice). Again, knockout (KO) of the 15-PGDH gene was highly effective in preventing colonic ulceration, supporting the idea that the therapeutic effect of SW033291 is mediated via inhibition of 15-PGDH.

[0169] Figure 6 (A-B) shows an example of scoring of the colonic mucosa of mice according to the Murine Endoscopic Index of Colitis Severity (MEICS) (Becker C. et al. Gut 2005;54:950-954). Figure 6A shows colonoscopic findings and MEICS scores for DSS-treated mice fed SW033291. Figure 6B shows colonoscopic findings and MEICS scores for DSS-treated mice fed vehicle only.

[0170] Figure 7 shows a graph of MEICS scores for DSS-treated mice given SW033291 (treatment; right) and vehicle (control; left). MEICS scores show significantly lower colitis activity in SW033291-treated mice on days 8, 11, and 15 of the study.

[0171] In addition to scoring colitis activity by gross visual inspection and the MEICS index, full-length mouse colons were formalin-fixed and paraffin-embedded and microscopically scored for crypt damage using the 0-4 severity scale of Cooper HS. Et al., Lab Invest. 1993;69:238-249. For this analysis, the colon was divided into three segments, the proximal, mid, and distal colon, each approximately 1.6 cm long, and each segment was further subdivided into four sections, each approximately 4 mm long. For each section, the crypt damage severity score was multiplied by the length of the damaged area (mm) to create a crypt inflammation severity index ranging from 0 to 16. The average crypt inflammation severity index was calculated for each segment (proximal, mid, and distal colon) and a combined whole-colon crypt inflammation severity index was determined for each mouse colon on a scale of 0 to 48. Similar to the visual MEICS score, the microscopic crypt inflammation severity index on day 8 of the DSS protocol was significantly higher (P<0.05) in control mice (score of 9.49) than in SW033291-treated mice (score of 3.16) (data presented but not shown).

[0172] Figure 8 shows an evaluation of the effect of SW033291 on maintaining DNA synthesis in the colonic mucosa of DSS-treated mice. Mice were IP injected with BrdU at 100 mg / kg 3 hours before sacrifice, and then full-length colons were formalin-fixed and paraffin-embedded. S-phase cells with BrdU incorporated into their DNA were visualized by immunofluorescence staining of 5 μm-thick sections with an antibody that detects BrdU. Colonic crypts were visualized by immunofluorescence staining with an antibody against E-cadherin, a marker of epithelium. Photograph insets show photomicrographs of high-power fields taken from the central colon at day 8 of the DSS protocol from control, SW033291-treated (treated) and 15-PGDH knockout (KO) mice. Red immunofluorescence identifies BrdU-positive nuclei and green immunofluorescence identifies E-cadherin-positive colonic cells. The number of BrdU positive cells per crypt is determined by counting the number of double-labeled red and green cells per average crypt. Green-only cells that are not in S-phase are not counted, nor are red-only cells that are likely interstitial cells outside the crypts. In the photomicrographs shown, the crypts are displayed in a vertical orientation in control and SW033291-treated mice, and in the 15-PGDH knockout mice, the crypts are displayed in a horizontal orientation. In the photographs, the number of S-phase cells is lowest in the control mice, increased in the SW033291-treated mice, and further increased in the knockout mice. In the particular photograph shown, both crypts from the control mice are devoid of S-phase cells and are visually reduced in height. However, the crypts shown from the SW033291-treated mice have increased crypt height, and the crypts shown from the 15-PGDH knockout mice have increased crypt height. Graph represents the sum of the mean number of BrdU positive cells per crypt in the distal colon and the mean number of BrdU positive cells per crypt in the mid-colon of control mice (Cn), SW033291-treated mice (Tx) and 15-PGDH knockout mice (KO) on days 1, 8 and 15 of the DSS treatment protocol.At day 8, SW033291-treated mice exhibit 5.7-fold higher numbers of BrdU-positive cells than control mice, which lost 85% of the value of BrdU-positive cells per crypt at day 1. 15-PGDH knockout mice showed no loss of BrdU-positive cells in crypts at day 8, consistent with the protective effect of SW033291 being mediated by inhibition of 15-PGDH.

[0173] Table 2 shows an overview of colon length (cm) in SW033291-treated mice and vehicle-treated control and 15-PGDH knockout (KO) mice sacrificed on days 8, 15, and 22 in DSS-treated mice, where colon shortening is a measure of disease activity. [Table 2]

[0174] Vehicle-treated control mice show significantly greater colon shortening compared to SW033291-treated mice (P=0.012) on day 22. This comparison is also shown graphically in FIG.

[0175] Table 3 summarizes mouse weight (grams) and colon length (cm) on the day of sacrifice for DSS-treated mice given SW033291 or vehicle control. [Table 3]

[0176] At day 22, SW033291-treated mice exhibited greater body weight and greater colon length, indicating the therapeutic effect of SW033291 in protecting against DSS-induced colitis.

[0177] Example 2 Identification of signaling networks associated with 15-PGDH expression To identify signaling networks that were significantly correlated with 15-PGDH gene expression in colon tissues, we first used an integrated pathway network modeling framework, PARADIGM (Vaske, CJ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-245(2010)) to comprehensively characterize the activities of exhaustive pathway networks across all 16 normal colon tissue samples. The PARADIGM analytical framework utilizes measurements of gene expression for a given sample to explicitly model the regulatory relationships detailed in a given signaling network and estimate the biological activity state of each of the signaling network's components in a tissue sample (Varadan, V., Mittal, P., Vaske, CJ & Benz, S. C. The integration of biological pathway knowledge in cancer genomics: A review of existing computational approaches. IEEE Signal Processing Magazine 29, 35-50(2012);Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337(2012);Cancer Genome Atlas, N. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70(2012);tlas, TCG Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615(2011)).PARADIGM incorporates known signaling network information curated in public databases such as the National Cancer Institute's Pathway Interaction Database (NCI-PID), the Reactome pathway database and the BioCarta pathway database, and provides an integrated signaling network structure (SuperPathway) containing more than 17,000 concepts representing 7,324 proteins, 1,574 protein families, 7,813 complexes and 586 processes (Schaefer, CF, et al. PID: the Pathway Interaction Database. Nucleic acids research 37, D674-679 (2009); Croft, D., et al. The Reactome pathway knowledgebase. Nucleic acids research 42, D472-477 (2014)). Thus, PARADIGM utilizes gene expression data obtained for genes in the SuperPathway network to infer sample-specific activity levels, termed Integrated Pathway Levels (IPLs), for each of the network components in the SuperPathway network. IPLs typically distribute between -1 and +1, with negative IPLs corresponding to lower activity and positive IPLs corresponding to higher pathway-specific activity.

[0178] Therefore, we used PARADIGM to estimate the Integrated Pathway Level (IPL) for each of the SuperPathway network components by analyzing the normalized log2-transformed gene expression values ​​across all of the normal colon tissue samples (N=16), and then evaluated the correlation between the IPL and the normalized 15-PGDH gene expression across all of the components in the SuperPathway. The degree of correlation and statistical significance was determined using Spearman's rho statistic. Pathway network components with a Spearman correlation p-value of 0.01 or less were considered significant, and the resulting subnetworks and their regulatory relationships were plotted using Cytoscape (Shannon, P., et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13, 2498-2504(2003)). The resulting interconnected component subnetworks provide insight into the activity of transcription factors associated with 15-PGDH gene expression across all of the normal colon tissues.

[0179] To further evaluate the likelihood of identifying a subnetwork of a given size purely by chance, we performed 10,000 randomized experiments. In each iteration, we randomly selected as many network components from the SuperPathways as were originally identified to be significantly associated with 15-PGDH expression. Then, for each iteration, we determined the size and number of connected subnetworks derived from these random component selections. The resulting distribution of subnetwork sizes from the 10,000 random iterations was modeled as a Poisson distribution, thus allowing us to estimate the probability of obtaining a subnetwork of a given size purely by chance.

[0180] FIG. 10 illustrates that by examining the sub-networks of the PARADIGM SuperPathway whose activity is significantly correlated with the expression of the 15-PGDH gene in normal colon tissues, the activity of the sub-network centered on the glucocorticoid receptor NR3C1 is identified as being significantly correlated with the expression of the 15-PGDH gene in normal human colon. Pathway components showing significant activity correlation with the expression of the 15-PGDH gene across all 16 normal colon cancer tissues (Spearman's correlation p-value ≦0.01) are plotted in red (positive correlation) and green (negative correlation) shades along with their regulatory relationships, with darker colors corresponding to higher absolute correlations. The size of the node corresponds to the statistical significance of the correlation. The p-value assigned to each sub-network is the probability of obtaining a sub-network of this size purely by chance.

[0181] Example 3 Combination of corticosteroids and 15-PGDH inhibitors We have previously demonstrated that SW033291, an inhibitor of 15-PGDH, is active in treating DSS-induced colitis, a mouse model of ulcerative colitis. This example provides novel findings showing that 15-PGDH inhibitors synergistically improve corticosteroid treatment of DSS-induced colitis, a mouse model of ulcerative colitis.

[0182] Figure 11A shows a schematic of a study in which mice were administered dexamethasone daily for three days and sacrificed for analysis 6 hours after the third dose. Figure 11B shows a representative Western blot analysis showing dexamethasone induction of 15-PGDH protein in mouse colon at two different doses of dexamethasone. Figure 11C shows a graphical summary of real-time RT-PCR from all mice in the study showing that dexamethasone treatment nearly doubled colonic 15-PGDH expression levels.

[0183] Figure 12A shows the schematic of the nearly doubled enzyme activity of 15-PGDH in the colon of mice treated with dexamethasone. Figure 12B shows the discovery that corticosteroids increase the activity of colonic 15-PGDH, suggesting that these agents paradoxically induce a negative feedback loop that may slow the healing of colonic mucosa in ulcerative colitis and intestinal mucosa in Crohn's disease. These findings predict that combining corticosteroid therapy with 15-PGDH inhibitors will improve the efficacy of corticosteroid therapy in ulcerative colitis and Crohn's disease.

[0184] Figure 13 (A-B) shows that higher dexamethasone doses exacerbate the induction of colitis by DSS. Eight-week-old FVB / NJ male mice were exposed to 2% DSS in drinking water in parallel with daily intraperitoneal injections of dexamethasone at the indicated doses (0 mpk (diamonds), 0.06 mpk (squares), 0.3 mpk (triangles), 3.0 mpk (x)). To compare the effect of increasing dexamethasone doses on the induction of colitis, daily body weights and disease activity indices (severity of diarrhea and bloody stools) were compared and graphed as shown (mean ± SEM; N = 5-8), where relative daily body weights are shown in Figure 13A and daily disease activity is shown in Figure 13B. Higher doses of dexamethasone significantly exacerbated the induction of colitis. Mice given 0.3mpk or 3mpk dexamethasone exhibited significantly worse weight loss, and mice given 3mpk developed significantly worse disease activity compared to the lower doses.

[0185] Figure 14 shows a schema of a study in which mice are given 2.5% DSS in drinking water for 7 days (days 1 to 8), a regime to induce colitis in mice. Then, starting on day 8, mice are treated with either vehicle control; 15-PGDH inhibitor-(+)SW033291 (abbreviated as (+)291) at 5 mpk IP twice daily; dexamethasone (abbreviated as dex) at 0.06 mpk IP daily; or a combination of (+)SW033291 at 5 mpk IP twice daily and dexamethasone at 0.06 mpk IP daily (mpk=mg / kg).

[0186] Figure 15 shows the daily body weights of mice on days 1-17 of the study, where mice were treated with control (diamonds), SW033291 (squares), dexamethasone 0.06 mpk (triangles) and a combination of both SW033291 and dexamethasone (x). Both (+)SW033291 treatment (squares) and dexamethasone treatment (triangles) as single agents improved weight loss somewhat, but the combination of (+)SW033291 with dexamethasone (x) was significantly more effective.

[0187] Figure 16 shows disease activity as measured by the Disease Activity Index (DAI) (scale of 0-6), which combines diarrhea (scale of 0-3) and blood in the stool (scale of 0-3). Mice were treated with control (diamonds), SW033291 (squares), dexamethasone 0.06 mpk (triangles) and a combination of both SW033291 and dexamethasone (x). Both (+)SW033291 treatment as single agents (squares) and dexamethasone treatment (triangles) improve DAI somewhat, but the combination of (+)SW033291 and dexamethasone (x) was significantly more effective.

[0188] Figure 17A graphs these results showing area under the DAI curve (total DAI) and in Figure 17B percent reduction in total DAI (relative disease reduction) is graphed. Single agent (+)SW033291 reduced total DAI by 14%. Single agent dexamethasone reduced total DAI by 15%. However, the combination of (+)SW033291 and dexamethasone reduced total DAI by 35%.

[0189] FIG. 18 graphs the survival rates of mice receiving control, dexamethasone, SW033291 and combination treatments for each day up to day 16 in the disease model (N=12 per group). * p<0.05 (Mantel-Cox test).

[0190] Figure 19 regraphs the data from Figure 17B with the order of group presentation permuted along with p-values. The combination group (green bars) is significantly improved compared to control (blue bars) or dexamethasone (yellow bars) or (+)-SW033291 (red bars) and outperforms any of the monotherapy regimens. Mean + SEM (N = 6 per treatment group). ** p<0.01, *** p<0.005 (by ANOVA and Student's t-test).

[0191] Figure 20 (A-D) shows representative endoscopic images of each group ((A) control, (B) dexamethasone, (C) SW033291, and (D) combination) on day 13 of treatment. Signs of mucosal bleeding and decreased wall transparency were evident in the control group, but decreased wall transparency is more pronounced in the dexamethasone group when compared to (+)-SW033291 or combination.

[0192] FIG. 21 shows a graph of the Mouse Endoscopic Index of Colitis Severity (MEICS) score on day 13 for each treatment group (control, dexamethasone, SW033291, and combination) as mean + SEM (N = 8-10 per treatment group). **p<0.01, *** p<0.005 (by ANOVA and Student's t-test).

[0193] Figure 22 (A-D) shows representative histology of the distal colon for each treatment group ((A) control, (B) dexamethasone, (C) SW033291, and (D) combination) on day 13. Disruption of epithelial crypt architecture was more pronounced in both control and dexamethasone-treated mice compared to mice treated with (+)-SW033291 or combination. Scale bar: 200 μm.

[0194] FIG. 23 shows a graph of the histological extent of inflammatory damage to the crypts, scored semi-quantitatively. ** p<0.01, *** p<0.005 (by ANOVA and Student's t-test).

[0195] Figure 24 shows a graph of the severity of mesenteric lymphadenopathy as assessed by total weight of mesenteric lymph nodes normalized by body weight at day 13 for each treatment group (control, dexamethasone, SW033291, and combination). Mean + SEM (N = 11-16). *** p<0.005 (by ANOVA and Student's t-test).

[0196] Although the present invention has been shown and described in detail with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the scope of the invention as encompassed by the appended claims. All patents, publications and references cited in the foregoing specification are hereby incorporated by reference in their entirety.

Claims

1. In the manufacture of a medicament for treating colitis in a subject in need thereof, [Formula 1] 2. Use of a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor, or a pharma- ceutically acceptable salt thereof, in combination with dexamethasone, comprising the formula:

2. The use described in claim 1, wherein the colitis is dextran sulfate sodium (DSS)-induced colitis.

3. The use according to claim 1 or 2, wherein the dexamethasone induces the expression of 15-PGDH.

4. 1. A pharmaceutical composition for treating colitis in a subject in need thereof, comprising: Dexamethasone and the formula: [chemical 2] or a pharma- ceutical composition comprising a 15-PGDH inhibitor having the formula:

5. The pharmaceutical composition described in claim 4, wherein the colitis is dextran sulfate sodium (DSS)-induced colitis.

Citation Information

Patent Citations

  • Treatment of inflammatory bowel disease (ibd)

    JP2008536855A

  • Compositions and methods for modulating 15-PGDH activity

    JP2015514770A

  • Compositions and methods of modulating short-chain dehydrogenase activity

    WO2015065716A1